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Background to Dissertation Project 
As the hormonal form of vitamin D, 1,25-dihydroxyvitamin D (l,25(OH)2D) serves 
as a major physiologie regulator of mineral metabolism in man (Haussier and McCain, 1977). 
The synthesis of l,25(OH)2D from its precursor 25-OH-D occurs in the proximal tubules of 
the kidney (Kumar, 1990) in a highly regulated fashion. The physiological demands for 
calcium are met in response to small incremental decreases in plasma calcium, which cause 
an elevation of a second calcitropic hormone, parathyroid hormone [PTH] (Fraser, 1980). 
This increase of PTH mediates the continuous work involved in protecting from bone loss 
and ensuring the long-standing integrity of bone mass. 
In the kidney, PTH is involved in the regulation of two critically important 
cytochrome P-450-linked mixed function oxidase enzymes, 25-OH-D-24- and la-
hydroxylases (24-OHase and la-OHase). In virtually reciprocal proportions, the activity of 
24-OHase decreases, whereas that of la-OHase increases (Kumar, 1984). Down-regulation 
of renal 24-OHase is essential because high concentrations of this enzyme can contribute to 
the inactivation of vitamin D (Kumar, 1986; Jones et al., 1987). As plasma 1,25(OH)2D 
concentrations increase in response to PTH, the actions of vitamin D are initiated at distinct 
sites in vitamin D target organs, which possess highly specific and saturable nuclear receptors 
for 1,25(0H)2D (Walters, 1985). By a mechanism not entirely understood, l,25(OH)2D 
stimulates the enterocytes of the small intestine to actively transport calcium, and 
independently, actively stimulate transport of phosphorus from the intestinal lumen to the 
blood (Wasserman, 1981). Eventually, the mineral needs of the organism are met, and, 
analogous to other classical endocrine loops, l,25(OH)2D mediates a suppression of PTH 
release (Slatopolsky et al., 1992) and thereby shuts down its own synthesis. 
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In addition, compensatory mechanisms primarily involving the action of calcitonin to 
lower plasma calcium by decreasing mobilization of bone calcium stores (Holtrop et al., 
1974) and facilitating the calciuric response (Marx et al., 1973). Overall, the major functions 
of 1,25(0H)2D are to mineralize the skeleton by elevating plasma calcium and phosphorus 
(Kumar, 1986; DeLuca, 1992). Besides intestinal calcium absorption, 1,25(OH)2D, in 
concert with PTH, mediates the mobilization of bone calcium (Raisz et al., 1972; Suda et al., 
1992) as well as renal reabsorption of calcium (Yamamoto et al., 1984). The elaborateness of 
the vitamin D endocrine system is such that there is dependence upon several systems for the 
integration of the appropriate mineralization of the skeleton and proper maintenance of 
calcium homeostasis. Because of this dependency, it is not difficult to understand that 
anomalous function in any one or more of the systems supporting vitamin D action can 
disrupt markedly the integrity of the whole system. Under normal circumstances, the action 
of 1,25(0H)2D at the tissue level is largely dependent upon tissue responsiveness (Roth et 
al., 1979; Chen et al., 1986). In turn, tissue responsiveness is dependent upon such factors as 
plasma l,25(OH)2D concentration, the concentration of l,25(OH)2D-receptor (VDR), and 
the rate of tissue-specific inactivation of l,25(OH)2D (Reinhardt and Horst, 1989; Reinhardt 
et al., 1988). 
The focus of this project was to examine the physiological and tissue-specific 
mechanisms involved in the regulation l,25(OH)2D action in the target tissues of rats. The 
model used in this project was developed on the basis of several studies that together suggest 
that the abundance and regulation of VDR in vitamin D target tissues precisely correlate with 
the specific physiological and metabolic status of the organism [embryonic development, 
early and adolescent growth, pregnancy, lactation, aging] (Halloran and DeLuca, 1981; Goff 
et al., 1988; Horst et al., 1990). The regulation of VDR also occurs in balance with the 
particular bone and mineral metabolism demands of the organism, especially in the form of 
dietary Ca, P, and vitamin D (Favus et al., 1988; Goff et al., 1990). To study the mechanisms 
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influencing tissue responsiveness to l,25(OH)2D action, I designed a model in which I 
examined the interaction of two commonly occurring metabolic disturbances — dietary 
calcium restriction and vitamin D toxicity. During dietary Ca restriction, renal tissue appears 
to be insensitive to many actions of l,25(OH)2D despite the fact that Ca restriction greatly 
stimulates endogenous production of l,25(OH)2D. In contrast, vitamin D toxicity leads to 
hypersensitivity of vitamin D target tissues despite low or unchanged 1,25 (OH) 2D 
concentrations. I address the effects of Ca restriction and vitamin D3 toxicity on vitamin D3 
target tissue responsiveness more thoroughly in the review chapter of this dissertation. The 
research herein provides meaningful information toward the development of effective 
programs to combat many disorders of bone and mineral metabolism such as milk fever in 
dairy cattle, renal failure with ensuing secondary hyperparathyroidism, and osteoporosis. 
An Explanation of the Dissertation Organization 
This dissertation consists of a review of the pertinent literature and three separate 
manuscripts that are intended for publication as separate studies. Each paper is complete in 
itself, with an abstract, introduction, materials and methods, results, discussion, and 
references. Although I conducted the experimental and technical work presented in this 
dissertation, other qualified investigators also gave thier advice and support. The names of 
these co-authors and their addresses are included on the title page of each paper, and I use the 
pronouns 'we and our' to refer the authors in each paper. A general conclusions section of the 
combined results and conclusions is included after the third manuscript. The review chapter 
deals specifically with the regulation of l,25(OH)2D3 action in the target tissues of rats. 
Subjects in the review include regulation of the 1,25(0H)2D 3-receptor, vitamin D3 
hydroxylases, and calcium binding proteins. Literature cited in the General Introduction and 
Literature Review sections follows the General Conclusions section. 
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LITERATURE REVIEW 
The Structure of the 1,25(0H)2D Receptor 
The vitamin D receptor (VDR) is a member of the steroid, thyroid, and retinoic acid 
receptor family of proteins that mediate the regulatory activities of their respective ligands 
through transactivation (Evans, 1988). Interaction of steroid receptors with DNA is 
determined largely through a specific region composed of two zinc-coordinated finger 
structures in the amino-terminal half of the receptor (O'Malley, 1990). The zinc-finger region 
is regulated through a complex carboxyl-terminal domain that functions, in part, to bind 
activating ligand (Beato, 1989; Kumar et al., 1987). Unoccupied VDR does not bind as tightly 
to DNA as does occupied VDR (Haussier et al., 1988). The expression of recombinant 
human (h)VDR and of mutant versions of the h VDR as well as functional analysis have 
confirmed the structural organization predicted by the primary sequence of the receptor 
(Baker et al., 1988; McDonnell et al., 1989). 
A comparison of the deduced amino acid sequences of both human and chicken VDR 
with those of the steroid (Green et al., 1986; Micheline et al., 1987; Hollenberg et al., 1985) 
and thyroid hormone receptors indicates that there are regions of extensive homology 
between these molecules. The most highly conserved region (C-1) within the human and 
chicken VDR sequences is a 70-amino acid, cysteine-rich region at the amino terminus of 
VDR, a region that is 96% conserved between the human and chick VDRs. By using this 
conserved sequence of human VDR as the basis for comparison with other steroid hormone 
receptors, 49,46,41, and 39% similarity is found in this region with human thyroid receptor 
(TR), human estrogen receptor (hER), human progesterone receptor (hPR), and human 
glucocorticoid receptor (hGR), respectively. Even more remarkable than the overall 
homology is the positional conservation of nine cysteines in the steroid, thyroid, and vitamin 
D receptors. It has been suggested that these closely paired cysteines coordinately bind zinc 
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and form fmger-like structures that intercalate into the major groove of DNA (Berg, 1988), 
much as that proposed for the transcription factor TFl 11A (Vincent, 1986). 
The second region of conservation (C-2) extends over 62 amino acids and is 
contained wholly within the hormone-binding domain of the receptors. Within this region, 
approximately 30% of the amino acids are conserved among the steroid receptors (Maxwell 
et al., 1987). An alignment of hTR and h VDR with these conserved peptide stretches reveals 
a third region (C-3) of similarity extending over 50 amino acids at the carboxyl terminus. 
Here, there exists approximately 33% homology between h VDR and hTR. No detectable 
relationship in this region is evident between h VDR and hER, hGR, or hPR. However, a 
comparison of this region within each of the steroid receptors among different species reveals 
a very high degree of conservation. Of the members of the steroid receptor family, h VDR 
exhibits the lowest molecular mass at 48 kDa and contains only 21 amino acids at the N-
terminal side of the DNA-binding domain (C-1). In contrast, the other steroid and thyroid 
receptors have additional N-terminal sequence, which accounts for their larger size. Another 
observation of VDR is that the hinge region, separating CI and C2, consists of 156 amino 
acids, which represent the longest such region observed in this class of receptors; it varies 
typically from 92 to 101 amino acids in hGR, and hPR, respectively. This enlarged hinge is 
evident in human as well as rat and chick VDR sequences, illustrating that the insertion is 
conserved and is not the result of a cloning artifact. Recent data on PR gene expression 
suggest that the "hinge domain" of PR receptors bind to other proteins involved in regulating 
gene expression. (Adler et al., 1988). 
The Distribution of the l,25(OH)2D Receptor 
The VDR is a nucleoprotein of 55,000 molecular weight in most mammals and is 
slightly larger in the avian species, 60,000 (Haussier et al., 1988). The discovery of the VDR 
has led to several studies that have revealed the existence of VDR in many tissues other than 
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the classical vitamin D target tissues, bringing to light a new appreciation of the versatility of 
vitamin D action (Link and DeLuca, 1985; Stumpf et al., 1979). The list of target organs 
continues to grow at a rapid pace and portends a vast new frontier of investigation for 
researchers in this field. Some of the nonclassical tissues found to possess VDR and 
therefore display responsiveness to l,25(OH)2D include: islet cells of the pancreas, cells of 
the parathyroid gland, certain cells of the ovaries, certain brain cells, skin fibroblast, 
keratinocytes, and many others recently summarized and reviewed by Lowe et al. (1992) and 
Walters (1992). 
Transactivation of the l,25(OH)2D Receptor 
The VDR bears close resemblance to a ligand-activated transcription factor by 
binding to specific genomic response elements (VDRE) located in the 5'-promoter regions of 
several target genes. The VDREs of many genes responsive to l,25(OH)2D were elucidated 
by means of reporter gene systems, and it has been demonstrated that VDR can bind to these 
sites with or without the aid of bound ligand (Darwish and DeLuca, 1993). However, cell-
free in vitro systems show that VDR requires an accessory protein or proteins for its 
association with a genomic VDRE (Liao et al., 1990; MacDonald et al., 1991; Sone et al., 
1991; Ross et al., 1992). This accessory protein, originally termed nuclear activation factor 
or NAF, is functionally similar to the cloned and sequenced receptor referred to as RXR, 
which stands for retinoic acid X receptor. Importantly, the RXR has three isoforms; RXR a, 
RXRP, and RXRy, each with very diverse tissue distribution (Mangelsdorf et al., 1992). 
Besides interacting with VDR for transactivation of gene expression (Kliewer et al., 1992), 
RXR also interacts with the receptors for retinoic acid and thyroid hormone (Kliewer et al., 
1992; Zhang et al., 1992). 
Recently, the discovery of the ligand for RXRa was made by two independent groups 
(Heyman et al., 1992; Levin et al., 1992). The ligand is 9-cis retinoic acid (9-cis RA) and has 
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a reported affinity with RXRa of 9.5-11.7 nM (Heyman et al., 1992; Levin et al., 1992), is 
produced naturally (Levin et al., 1992), and can bind with high affinity with RXRP and 
RXRy (Mangelsdorf et al., 1992). 
The putative interaction of RXR/NAF with VDR is that of a heterodimer formation 
through a leucine zipper interaction between the proteins (Freedman and Towers, 1991; 
Forman and Samuels, 1990). The interaction of RXR/NAF with VDR confers 
responsiveness of VDR for transactivation of gene expression. However, it is still unclear 
whether the presence of the substance 9-cis RA eliminates the ability of RXR/NAF to form 
heterodimers with VDR, thereby destabilizing the transactivation process or is necessary for 
VDR transactivation. In the genes studied so far, the presence of 9-cis RA enhances the 
transcriptional activation of these genes (Mangelsdorf et al., 1992; Heyman et al., 1992), but 
this remains to be shown for the transcriptional activation of a vitamin D-dependent gene. 
On the contrary, initial but unpublished data (Pike, 1992) indicate that increasing 9-cis RA 
concentration in a cell-free culture system enriched with RXR/NAF and VDR inhibited 
transactivation, as expressed by chloramphenicol transferase activity. This surely will be an 
enlightening area of investigation in the coming months and years. The most striking facet 
from all of this is the enormous physiological diversity of tissue-specific and cellular 
signaling that exists with the interactions of the RXR/NAF, thyroid hormone, retinoic acid, 
1,25(0H)2D receptors, and now knowledge of the presence of the 9-cis RA ligand for 
RXR/NAF and RARs, in addition to all-trans RA. Furthermore, it is not yet clear if 9-cis RA 
is the sole ligand for RXR/NAF binding (Heyman et al., 1992). 
The Regulation of the l,25(OH)2D Receptor 
Because of the direct relationship between the l,25(OH)2D-VDR activation and 
biological responses, regulation of the VDR is crucial to the modulation of target cell 
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responsiveness to the hormone. In 3T6 mouse fibroblasts, induction of VDR mRNA has 
been demonstrated in concert with enhanced receptor protein concentrations and 
posttranslational phosphorylation on a serine residue(s) (Haussier et al., 1988; McDonnell et 
al., 1987). In vitro, ligand-dependent up-regulation of VDR mRNA also has been 
demonstrated to occur in human and rat osteosarcoma cell lines (Reinhardt and Horst, 1990; 
Mahonan et al., 1990), respectively, and in human leukemia cells [HL-60] (Lee et al., 1989; 
Pan et al., 1989). The concentration of VDR in the l,25(OH)2D target sites is thought to 
modulate the effect of the l,25(OH)2D. Therefore, ligand-dependent up-regulation of the 
VDR was demonstrated to occur in rat intestine (Costa & Feldman, 1986; Huang et al., 1989) 
and parathyroid gland (Naveh-Many et al., 1990) at the level of VDR mRNA and in bone 
cells (Reinhardt et al., 1989), kidney, and intestine (Goff et al., 1990) at the level of VDR 
protein content. The finding that mutations in the VDR gene result in l,25(OH)2D-resistant 
rickets confirms the importance of the VDR in mediating the actions of vitamin Dg (Hughes 
et al., 1988; Ritchie et al., 1989). Equally important is the recent evidence that the 
l,25(OH)2D-VDR complex modulates transcription of PTH (Silver et al., 1985; Silver et al., 
1986; Okazaki et al., 1988) and calcitonin (Naveh-Many and Silver, 1988; Cote et al., 1987), 
both of which are decreased in transcription. 
The DNA sequences in the rat and human osteocalcin genes that bind VDR and 
confer responsiveness to l,25(OH)2D were characterized (Kemer et al., 1989; Demay et al., 
1990; Markose et al., 1990). Binding of VDR to these sequences provides further evidence 
that 1,25(0H)2D binds to its receptor and causes activation of gene transcription analogous to 
that of other small non-peptide hormones (Yamamoto, 1985). A transfection assay, in which 
both a VDR cDNA expression plasmid and a reporter plasmid containing the vitamin-D-
responsive osteocalcin promoter were introduced together into host mammalian cells, 
confirmed the transcriptional activation of the osteocalcin promoter by 1,25(0H)2D 
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(McDonnell et al., 1989). From these experiments, a vitamin D responsive element (VDRE) 
was elucidated, which is located 400-500 base pairs upstream of the transcriptional start site 
of the promoter domains of human (Kemer et al., 1989) and rat (Demay et al., 1990; Markose 
et al., 1990) osteocalcin genes. As with the osteocalcin gene, studies are now underway to 
map the 5'-regulatory domain of the intestinal and kidney calbindin (calcium binding 
proteins; also known as CaBP-9K, and CaBP_28K)> 24-OHase, and osteoponton genes based 
on structural and functional data indicating l,25(OH)2D3 inducibility (Dupret et al., 1987; 
Krisinger et al., 1988). 
The current understanding of VDR regulation is limited in large part to in vitro 
analyses of VDR concentrations in a variety of cultured cell types (Reviewed by Walters, 
1992). The relationship between VDR modulation and biological function has been examined 
in this way and the biologic response, for example, stimulation of osteocalcin synthesis, 
inhibition of collagen synthesis, and induction of 25-hydroxyvitamin D-24-hydroxylase 
activity, was found to correlate well with increases in VDR concentration in the cultured cells 
at the confluent stage. Unfortunately, the molecular mechanisms of receptor modulation and 
its relationship with receptor-mediated bioresponses are entirely unknown. The binding 
characteristics of 1,25 (OH) 2D hormone receptor complexes and individual genes for each 
biological response have not yet been studied. To carry out this kind of study, the 
identification and isolation of each functional gene is required, including their regulating 
regions and characterization of their binding properties with purified VDR. To understand 
the underlying relationships between the binding of hormone-receptor complexes to DNA 
and the subsequent expression of the gene, one would have to map the regulatory regions of 
the gene and study the binding characteristics of the hormone-receptor complexes with the 
receptor binding sites at the regulatory region. Two or more genes with different biological 
effects should be studied. Aside from the differences in receptor-gene interaction at the 
transcriptional level, other possible differences may exist at the post-transcriptional and post-
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translational levels, which also could alter the expression of each gene. Such mechanisms 
include the relative stability of mRNA and the degradation and modification of each induced 
protein. Experiments to obtain complementary DNA (cDNA) encoding the avian 
(McDonnell et al., 1987), human (Baker et al., 1988), and rat (Mangelsdorf et al., 1987) have 
been accomplished, but the use of cDNA probes for cloning the VDR gene has so far failed 
in isolating enough of the 5'-flanking region of the VDR gene to comprise the regulatory 
promoter domains. Sequencing this domain will be extremely useful in locating consensus 
sequences for putative VDR response elements (VDRE). 
Because of the steroid hormone-receptor transactivation nature of l,25(OH)2D 
bioresponsiveness, VDR regulation can be defined as the quantitative and qualitative changes 
in VDR that take place over a defined period of time, such as a day or a week. The changes 
in VDR could be characterized by altered target site responsiveness to l,25(OH)2D. For 
example, Costa and Feldman (1986) first demonstrated that exogenous administration of a 
pharmacological amount of l,25(OH)2D resulted in increased intestinal VDR concentration 
that correlated with enhanced intestinal calcium absorption. The increase in intestinal VDR 
in response to l,25(OH)2D is analogous to a positive feed-forward mechanism termed 
homologous up-regulation. Since the initial discovery demonstrating l,25(OH)2D induction 
of homologous regulation of VDR concentration, several investigators similarly have shown 
the phenomenon to occur in many different systems in vitro and in vivo (Haussier et al., 
1988). Therefore, the emerging model of l,25(OH)2D action is that VDR acts upon upstream 
enhancer elements to induce or repress specific gene transcription, or both. This results in 
specific regulation of protein synthesis required for maintenance of calcium homeostasis by 
the classic target tissues, which include intestine, bone, and kidney (Haussier and McCain, 
1977). In addition, many new target tissues and functions recently have been attributed to 
1,25(0H)2D (Walters, 1992; Reinhardt and Hustmeyer, 1987). 
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It was hypothesized by Reinhardt et al. (1988) that tissue VDR concentration is 
modulated by a complex set of regulatory mechanisms including homologous and 
heterologous factors. In addition to extracellular and intracellular concentrations of 
1,25(0H)2D and the abundance of target cell VDR, tissue responsiveness also is dictated by 
tissue-specific catabolism or inactivation of l,25(OH)2D, which substantially can determine 
the biologic response in these tissues during such climacteric states as pregnancy and 
lactation. 
It is proposed that both VDR numbers and the metabolic half-life of l,25(OH)2D 
varies from tissue to tissue. It is well known that the higher tissue receptor concentration 
results in greater response to hormone (Roth et al, 1979; Chen et al., 1986). Interestingly, 
1,25(0H)2D homologously up-regulates its own receptor in kidney, bone, and intestinal 
tissues, which can enhance tissue responsiveness (Costa et al., 1985). In some tissues, 
however, this enhancement is counteracted by a similar induction by l,25(OH)2D of C-24/C-
23 enzymes that inactivate and terminate the biologic response to l,25(OH)2D (Reinhardt and 
Horst, 1989). The kidney is unique in that PTH action is targeted specifically at inhibiting 
24-OHase, the purpose of which seems to be for increasing the availability of substrate for 
1,25(0H)2D formation. It is therefore surprising that, given the potential in the kidney for 
the enhancement of tissue responsiveness, VDR up-regulation has never been demonstrated 
to occur in response to endogenous elevation of plasma 1,25(0H)2D, that has been induced 
by mineral deficiency. 
A possible mechanism has been suggested in a series of reports dealing with in vivo 
and in vitro VDR regulation. In the study of Goff et al. (1990) groups of rats were fed a 
0.02% Ca diet for one, two and three weeks, respectively. Restriction of dietary calcium led 
to low serum calcium concentration and a compensatory rise in PTH secretion. In turn, PTH 
stimulated a 6-fold increase of plasma l,25(OH)2D. However, intestinal VDR concentrations 
did not change and surprisingly kidney VDR concentrations were decreased significantly. 
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Their conclusion was that target tissue responsiveness was negatively modulated by a factor 
other than l,25(OH)2D during calcium deficiency. PTH was proposed as a potential 
candidate in tis regulation. The down-regulation of kidney VDR suggested the development 
of decreased l,25(OH)2D action in this tissue. 
In a second experiment designed by Reinhardt and Horst (1990), rats were coinfused 
via osmotic mini pumps, with PTH and l,25(OH)2D, the two factors that are increased 
endogenously with dietary Ca restriction,. The results showed that homologous up-
regulation of VDR (kidney and intestine) was blocked by the presence of PTH. 
In a third study, (Beckman et al., 1990) a hypervitaminosis D system was chosen, 
which is characterized by high plasma calcium, baseline secretion of PTH, and, therefore, 
little or no increase in l,25(OH)2D production. As expected, tissue responsiveness was 
enhanced greatly in correlation with increased intestinal VDR. 
The fourth study (Paper 2) was designed to examine the interaction of calcium-
restriction and excess vitamin D on VDR regulation. Initially the kidney was chosen as the 
model tissue because it is a known PTH target site. In this experiment, calcium restriction 
caused decreased plasma Ca and increased plasma PTH concentration in both normal and 
excess vitamin D rats. Again, the increase in PTH correlated directly with kidney VDR 
down-regulation and intestinal tissue refractoriness to excess vitamin D. 
From these four experiments it was proposed (Reinhardt and Horst, 1990) that cellular 
VDR numbers are controlled by calcium status and PTH as the likely candidate directly 
responsible for negative modulation of VDR by decreasing VDR expression in the kidney 
and the intestine. The response of VDR expression to hyperparathyroidism appears to be 
very potent and is capable of overriding the effects of l,25(OH)2D in a Ca-deficient animal. 
Also, PTH seems to act at the level of VDR gene transcription in the kidney and bone 
osteosarcoma cells (Reinhardt and Horst, 1990). Intestine is not a classic PTH target tissue, 
but the experiments just described suggest that PTH can, either directly or indirectly, prevent 
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l,25(OH)2D-induced intestinal VDR expression. Further examination of the mechanisms 
surrounding the regulation of target tissue responsiveness to l,25(OH)2D action were 
pursued by elaborating upon a model that combines the effects of dietary Ca restriction and 
vitamin D toxicity. The strong points of this model were: 1) careful use of dietary regimens 
proved effective in controlling plasma concentrations of Ca, l,25(OH)2D, PTH, and 
calcitonin, 2) Ca restriction and vitamin D toxicity are both metabolic disturbances that 
naturally occur occasionally in humans and other animals and, if left unattended, will result 
in severe impairment of organismal bone and mineral metabolism, and 3) the strikingly 
opposite effects of these two disorders on vitamin D tissue responsiveness lead to extremely 
quantifiable differences among tieatment effects in many instances. 
Vitamin D Hydroxylases 
The three major vitamin D hydroxylases that are particularly important in meeting the 
needs of Ca homeostasis are hepatic 25-hydroxylase (25-OHase) and renal la- and 24-
OHase. Vitamin D undergoes conversion to 25-OH-D both in hepatic microsomes and 
hepatic mitochondria (Ponchon and DeLuca, 1969; Bhattacharyya and DeLuca, 1974). 
Under normal conditions, the microsomal 25-OHase is operative, but this enzyme is 
negatively regulated by high plasma 25-OH-D concentrations (Fraser, 1980). The 
mitochondrial 25-OHase has a higher Km than the microsomal 25-OH-D and is more loosely 
regulated, so during situations of vitamin D toxicity, large amounts of vitamin D are 
converted to 25-OH-D by the mitochondrial 25-OHase systems (Bjorkhem and Holmberg, 
1979). The microsomal 25-OHase comprises a cytochrome P-450 that utilizes molecular 
oxygen and receives electrons from a flavo-protein NADPH-ferredoxin reductase (Yoon and 
DeLuca, 1980; Hayashi et al., 1988). The mitochondrial P-450 accepts electrons from 
NADPH-ferredoxin reductase and ferredoxin (Bjorkhem et al., 1980). 
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The 25-OH-D metabolite is converted in the proximal tubules of the kidney to either 
24,25(0H)2D, which occurs during normocalcemic conditions, or 1,25(OH) 2D, which is 
formed in response to hypocalcemic conditions. Both la- and 24-OHase have been partially 
purified (Hiwatashi et al., 1982; Ohyama and Okuda, 1991), and, like hepatic 25-OHase, the 
renal hydroxylases are cytochrome P-450 mixed-function oxidases. The components of the 
la-OHase are: a flavoprotein reductase, a non-heme-iron protein (ferredoxin), and a 
cytochrome P-450 terminal oxidase (Ghazarian et al., 1974; Pedersen et al., 1976; Yoon et 
al., 1980). The requirements of renal 24-OHase are NADPH and molecular oxygen 
(Pedersen et al., 1983). 
In a classical sense, 25-OH-D formation occurs in the liver, and l,25(OH)2D and 
24,25(OH)2D formations occur in the kidney. However, there is rather wide distribution of 
the three major hydroxylases among several classical and non-classical l,25(OH)2D target 
tissues. Besides the liver, 25-OHase activity also takes place in the intestine and kidney 
(Tucker et al., 1973; Bergman and Postlind, 1990). The reports for la-OHase show an even 
more extensive tissue distribution than that for 25-OHase including such tissues as placenta 
(Zerwekh and Breslan, 1986), bone (Howard et al., 1981), skin (Bikle et al., 1986), activated 
macrophages (Reichel et al., 1987), liver (Hollis, 1990), myeloid leukemia cells (Hewison et 
al., 1989), decidual tissue (Devlin and Arabian, 1987). For many of these newer tissue sites 
of la-OHase, the conversion of 25-OH-D to l,25(OH)2D may serve in a paracrine or 
autocrine role and not an endocrine role, but this issue is still debatable. 
The tissue distribution of 24-OHase activity is extremely diverse, and 24-OHase 
exists in nearly all of the l,25(OH)2D target tissues tested to date (reviewed by Walters, 
1992). The presence of 24-OHase in so many target-tissues of l,25(OH)2D along with the 
fact that 1,24,25(0H)3D has substantially less activity than even vitamin D3 in curing rickets 
(Holick et al., 1973), has given rise to the theory that 24-OHase is the initial step in the 
inactivation pathway of l,25(OH)2D. Other studies, however, suggest an active role of 
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24,25(0H)2D in bone (Omay et al., 1978), egg shell formation (Rambeck and Zucker, 1985), 
and egg hatchablity (Henry and Norman, 1978; Ameenuddin et al., 1982), and these claims 
have been difficult to refute. 
Many factors can influence the regulation of vitamin D hydroxylases in kidney - the 
most important of which are the concentrations of serum - Ca, phosphate, l,25(OH)2D, and 
PTH. 
Renal 1 a-OHase is most critically affected by low serum Ca (Rasmussen et al., 
1972), which stimulates the release of PTH (Garabedian et al., 1972). Presumably, PTH 
increases 1 a-OHase activity through a mechanism involving cAMP (Rost et al., 1981). 
Horiuchi et al., (1977) demonstrated that exogenous cAMP restored l,25(OH)2D3 
concentrations of TPTX, vitamin D-deficient rats, and the magnitude and time course of la-
OHase stimulation by cAMP was similar to those of PTH. One theory is that cAMP 
stimulates dephosphorylation of the ferredoxin subunit of 1 a-OHase, and this 
dephosphorylation event increases 1 a-OHase activity (Siegel et al., 1986; Nemani et al., 
1989). In addition, Korker et al. (1987) presented evidence for the requirement of new 
protein synthesis in the stimulation of 1 a-OHase by cAMP. Dietary phosphorus restriction 
also increases 1 a-OHase (Gray and Napoli, 1983), and the increase in la-OHase activity 
may be mediated by a mechanism involving growth hormone (Gray and Garthwaite, 1985). 
A decrease in la-OHase activity is mediated by l,25(OH)2D3 feedback (Tanaka and 
DeLuca, 1974) through an unknown mechanism, but one that putatively involves new protein 
synthesis (Omdahl et al., 1980). 
Tissue-specific metabolism of l,25(OH)2D to less active metabolites regulates 
l,25(OH)2D action in various target-tissues. In the liver and intestine, l,25(OH)2D 
undergoes side-chain oxidation to form an inert 23-carbon acid, calcitroic acid (Hamden et 
al., 1976; Esvelt et al., 1979). In the kidney, intestine, and cartilage, the enzyme 
l,25(OH)2D-24-OHase converts l,25(OH)2D to l,24,25(OH)3D, a metabolite with 
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decreased bioactivity (Holick et al., 1973; Garabedian et al., 1978) but one that can be 
detected in the blood of cows treated with vitamin D3 (Reinhardt et al., 1982). Furthermore, 
side-chain modifications of l,25(OH)2D can occur in various tissue-sites, whereby 
1,25(0H)2D can be converted to C-23, C-26-lactone products (Horst et al., 1984). All of 
these side-chain modifying enzymes are, in general, induced by 1,25 (OH) 2D and can account 
for 20-30% of the metabolism of l,25(OH)2D (Kumar, 1984). In addition, l,25(OH)2D may 
form conjugates with liver glucuronides and sulfates and be excreted into the bile (Kumar et 
al., 1980; Litwiller et al., 1982). Some of the conjugated 125(OH)2D becomes de-conjugated 
in the intestine and then is reutilized, the rest is lost in the feces. The major physiological 
function of the side-chain and enterohepatic clearance pathways can be thought of as 
processes that terminate the hormonal response, thereby preventing toxicity. 
The diverse tissue distribution of 24-OHase and the speculation by many that 24-
OHase represents the initial step in an inactivation pathway of 1,25 (OH) 2D, has made the 24-
OHase an intriguing enzyme system to study. In the kidney, PTH acts to suppress 24-OHase 
activity. This PTH-mediated suppression involves cAMP (Horiuchi et al., 1977; Shinki et 
al., 1992), but the molecular details of the mechanism are unclear. There is extensive, yet 
inconclusive, evidence indicating regulation of 24-OHase by post-translational modification 
of the P-450 (Ghazarian, 1990), or by phosphorylation/dephosphorylation of the renal 24-
OHase ferredoxin (Mandel et al., 1990). To date, the effect of PTH on suppressing 24-
OHase has been unique to renal 24-OHase. Studies in vitro seem to demonstrate, in nearly 
every tissue cell-line tested, that 24-OHase activity is l,25(OH)2D-inducible (Walters, 1992). 
Yet, it is not known whether these results occur in vivo in extrarenal target sites of 
l,25(OH)2D. So far, experiments done in vivo demonstrate seemingly stringent tissue-
specific control of 24-OHase mRNA induction, even when plasma l,25(OH)2D 
concentration is increased several-fold by Ca restriction (Paper 1; Paper 2; Walters, 1992). 
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The group of Okuda successfully purified 24-OHase from rat kidney mitochondria 
(Ohyama et al., 1989) and prepared specific antibodies against 24-OHase that led to the 
cloning of a cDNA encoding the enzyme (Ohyama et al., 1991). This cDNA has been useful 
for studying the regulation of 24-OHase at the level of transcription. Tomon et al. (1990a, b), 
inferred that l,25(OH)2D-mediated induction of 24-OHase is a pretranslational event by 
using transcriptional and translational inhibitors. Northern analysis has confirmed that 24-
OHase mRNA is induced by l,25(OH)2D in the intestine as well as the kidney, indicating 
that 24-OHase may be encoded by the same gene in both tissues (Armbrecht and Boltz, 1991; 
Ohyama et al., 1991; Shinki et al., 1992) 
Using the 24-OHase cDNA as a probe, Okuda's group now has characterized the rat 
24-OHase gene (Ohyama et al., 1993). This information indicates that a single gene encodes 
24-OHase. The gene contains 12 exons and spans about 15 Kbp. A total of 4 potential 
vitamin D responsive elements (VDRE) were found. Two of them show potential sequence 
similarity to known VDREs for rat calbindin-9k (Darwish and DeLuca, 1992) and rat 
osteocalcin (MacDonald et al., 1991) and are located in the region -427 to -409 of the gene, 
which correlates with the location of a VDRE in the osteocalcin gene. Two other VDREs are 
located in the region -210 to -196 of the gene and share greater sequence similarity to known 
VDREs than the first two. In addition, an Spl binding site, GGGCGG (GC box), is located 
at -385 to -380. However, a putative response element for cAMP or a protein kinase C, API 
binding site has not been identified despite functional data indicating an involvement of 
cAMP and protein kinase C in the regulation of 24-OHase (Horiuchi et al., 1977; Mandla et 
al., 1990). 
Potential Role of Calcitonin in Regulating Intestinal 24-OHase 
In the manuscript sections of the dissertation, I make a case for tissue-specific 
regulation of 24-OHase that requires some explanation here as well. To date, very little 
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information exists concerning regulation of extrarenal 24-OHase systems, but it is clear that 
the same calcitropic factors regulating renal 24-OHase, such as PTH, do not similarly 
regulate intestinal 24-OHase (Shinki et al., 1992). An improved understanding of how 
extrarenal 24-OHases are regulated is important because 24-OHase activity , in some tissues, 
may influence tissue-responsiveness to l,25(OH)2D action (Reinhardt and Horst, 1989). The 
intestine is of particular interest because of the role it plays in Ca absorption, Ca homeostasis, 
and , therefore, promotion of bone formation. A recent theory to emerge from my work is 
that calcitonin functions in suppressing intestinal 24-OHase activity (Paper 3). The 
implication of such suppression may be that there is less intestinal clearance of 1,25(OH) 2D 
during hypercalcemic states, such as vitamin D toxicity, sarcoidosis, and dietary phosphorus 
restriction. Prolonged intestinal stimulation by l,25(OH)2D would worsen these conditions. 
The mechanism by which calcitonin suppresses intestinal 24-OHase is now under 
investigation. 
The distribution of receptors for calcitonin (CTR) includes bone osteoclasts 
(Nicholson et al., 1986) where calcitonin acts to inhibit osteoclastic bone resorption (Holtrop 
et al., 1974) and in kidney (Marx et al., 1973) where calcitonin stimulates reabsorption of 
urinary Ca2+ as well as several other ions (Di Stefano et al., 1990). Recently published were 
cloning and nucleotide sequences of the cDNAs for CTR and PTH/PTH-related peptide 
receptors and their deduced amino acid sequences (Lin et al., 1991; Abou-Samra et al., 
1992). This information, along hydropathy analysis, has demonstrated the receptors to have 
substantial sequence identity (-32%) and sequence similarity (56%). Additionally, these 
receptors form a small subgroup of Ggg^-linked receptors that also include secretin receptor 
(Shihara et al., 1991) and most recently glucagon receptor (Jelinek et al., 1993). The 
hydropathy analysis of CTR indicates 7 to 8 regions of hydrophobic amino acids long enough 
to be membrane-spanning domains (Lin et al., 1991). What is unique about the receptors in 
this family is their ability to mediate cellular actions through at least two separate pathways 
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independent of the other (Thompson, 1992). Both calcitonin and PTH receptors can 
stimulate cAMP and Ca/IPg signaling pathways (Abou-Samra et al., 1992; Charbe et al., 
1992). This versatility of the calcitonin receptor, as well as its low abundance in target cells, 
has made it difficult to purify and study. The actual characterization of these receptors in 
intestinal mucosa of rat, however, awaits further investigation. 
In preliminary work in the laboratory of Horst, oligonucleotide probes we/e 
constructed from the published porcine calcitonin receptor (CTR) sequence (Lin et al., 1992) 
and demonstrated, by using the sensitive technique of reverse transcriptase-PCR, to hybridize 
with specific RNA fragments in total RNA samples prepared from porcine intestinal mucosa 
(unpublished data). These fragments are being sequenced, and hopefully, will match 
identically with the sequence of porcine CTR published by Lin et al. (1992) thus establishing, 
for the first time, the existence of CTR in intestinal mucosa. 
Concluding Remarks 
The following three papers present the experiments, methods, results, and conclusions 
of the effects of l,25(OH)2D action in kidney and intestine tissues of rats. In the first study, I 
examined the effects of dietary Ca restriction and vitamin D toxicity on the metabolic 
clearance and production rates 1,25(OH)2D and infer how changes in l,25(OH)2D MCR 
influence 1,25(OH) 2D action in a tissue-specific manner. The second study deals with the 
comparison of tissue responsiveness in kidney versus intestinal tissue. It is demonstrated that 
PTH exerts very potent down-regulation of factors associated with renal tissue 
responsiveness, but this same relationship could not be confirmed in intestinal tissue. In the 
final study, evidence is provided for a role of calcitonin on the down-regulation of intestinal 
24-OHase expression. Such a pattern of regulation potentially would block an important 
inactivation pathway of vitamin D and thereby enhance intestinal tissue responsiveness 
during vitamin D toxicity. 
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PAPER 1. TISSUE RESPONSIVENESS AND DETERMINATION OF 25-OH-D3 AND 
1,25(0H)2D3 CLEARANCE AND PRODUCTION RATES IN VITAMIN D3 
EXCESS AND CALCIUM-DEFICIENT RATS 
MATTHEW J. BECKMAN, ** YING-TING ZHU, ** DONALD C. BEITZ**AND 
RONALD L. HORST* 
* U.S. Department of Agriculture, Agricultural Research Service, National 
Animal Disease Center, Metabolic Diseases and Immunology Research Unit, Ames, 




We measured the metabolic clearance rates (MCR) and production rates (PR) of both 
25-OH-D3 and 1,25(OH)2D3 in control (NC, 1.0% Ca), vitamin Dg-excess (NCT, 1.0% Ca 
plus 75,000 lU Dg/wk), Ca-deficient (LC, 0.02% Ca), and Ca-deficient and vitamin D3-
excess (LCT, 0.02% Ca plus 75,000 lU Dg/wk) rats using the constant infusion method. In 
NC rats l,25(OH)2D3 MCR was 359.7 ± 44.6 ml x min'l x kg"l, and 25-OH-D3 MCR was 
19.3 ± 1.9 ml min"l jc kg'l. The 1,25(OH)2D3 and 25-OH-D3 PRs in NC rats were 37.4 ± 
7.0 pg X min'l x kg'l and 2.3 ± 0.5 ng % min"^ x kg"!, respectively. The NCT treatment 
stimulated an increase in 25-OH-D3 PR by 40.0-fold, whereas in LC rats 25-OH-D3 PR 
decreased by 5.0-fold as compared with NC rats. The LCT treatment increased 25-OH-D3 
PR by 17.4-fold, but this potentiation of 25-OH-D3 PR in LCT rats was only 44% of 25-OH-
D3 PR in NCT rats. The l,25(OH)2D3 PR of NCT rats increased by 3.0-fold and in LC and 
LCT rats by 5.6-and 6.2-fold, respectively. The l,25(OH)2D3 MCR of NCT rats increased 
by 3.5-fold, was unchanged in LC rats, and increased by 3.8-fold in LCT rats. Plasma 25-
OH-D3 and 24,25(OH)2D3 concentrations increased substantially in NCT rats (16.0- and 
27.0-fold, respectively), but in LC and LCT rats plasma 25-OH-D3 and 24,25(OH)2D3 
concentrations decreased by 40-60% as compared to plasma 25-OH-D3 and 24,25(OH)2D3 
concentrations of NC and NCT rats, respectively. Plasma l,25(OH)2D3 concentration was 
unchanged in NCT rats, in contrast with 4.3-fold increase in LC rats. However, in LCT rats, 
plasma l,25(OH)2D3 concentration increased by only 1.8-fold. In conclusion, increases in 
1,25(0H)2D3 PR and l,25(OH)2D3 MCR in LCT rats indicate the potential for substantial 
induction of extrarenal 25-OH-D3-1 «-hydroxylase and 24-hydroxylase activities. 
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INTRODUCTION 
Hypervitaminosis D3 (excess vitamin D3) and dietary Ca restriction both lead to 
metabolic disturbances that can alter target tissue responsiveness to 1,25-dihydroxy vitamin 
D3 [1,25(0H)2D3], the active metabolite of vitamin D3 (Vieth, 1990; Lebowitz and Moses, 
1992). Excess vitamin D3 acquired either by diet or iatrogenically will cause toxicity, and 
the severity depends upon such factors as the type of vitamin D (vitamin D2 or vitamin D3), 
the dose, the functional state of the kidneys, and the composition of the diet (Horst, 1988). 
The most important factor in causing vitamin D3 toxicity is the amount of dietary Ca, which 
when high will enhance vitamin D3 toxicity and when low decreases the toxic side effects of 
vitamin D3 accumulation (Hines et al, 1985). Vitamin D3 toxicity has been characterized as 
a disorder of intestinal hypersensitivity, for intestinal Ca absorption increases in an 
unregulated manner (Stem and Bell, 1989), despite diminished plasma l,25(OH)2D3 
concentrations, indicating enhanced vitamin D3 responsiveness in tissues (Cobum and 
Barbour, 1984). Furthermore, up-regulation of intestinal l,25(OH)2D3-receptors (VDR) has 
been shown to occur as a result of excessive dietary vitamin D3 (Beckman et al., 1990). In 
contrast, a decrease in l,25(OH)2D3 responsiveness occurs in rat kidney and intestine, during 
dietary Ca restriction, even though development of nutritional hyperparathyroidism leads to 
an increase in plasma l,25(OH)2D3 concentration by several-fold (Goff et al., 1990). 
Reinhardt and Horst (1990) demonstrated a potential parathyroid hormone (PTH) effect on 
down-regulating kidney VDR, however, the mechanism by which Ca restriction decreases 
intestinal tissue responsiveness is unclear. 
The kidney is one of the few target organs of vitamin D3 that is capable of extensive 
metabolism of vitamin D3 (Jones et al,, 1988). Two pathways of vitamin D3 metabolism in 
the kidney involve initial hydroxylations at the C-24 position (C-24, C-23 pathway) or either 
of the C-26 or C-23 positions (C-26, C-23-lactone pathway). The C-24, C-23 pathway is the 
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preferred pathway under normal physiological circumstances, and the end product of this 
pathway is calcitroic acid (Reddy and Tsemg, 1989; Makin et al., 1989). Alternatively, 
induction of hydroxylation at the C-26 and C-23 positions occurs when plasma vitamin Dg 
and 25-OH-D3 concentrations are in excess, and subsequent metabolism through this 
pathway eventually leads to the formation of C-26, C-23-lactone end-products (Horst, 1979; 
Wichmann et al., 1979). 
The C-24, C-23 pathway has been implicated to play a role in the metabolic clearance 
rate (MCR) of l,25(OH)2D3 by forming less active products of l,25(OH)2D3 (Horst et al., 
1986; Haussier et al., 1988). Besides the kidney, extrarenal tissues, including intestine 
(Kumar et al., 1978) and bone cells (Howard et al., 1981; Lohnes and Jones, 1987) have been 
shown to possess the enzyme 25-OH-D 3-24-hydroxylase (24-OHase), which can be induced 
by 1,25(0H)2D3 (Armbrecht et al., 1992). The intestine, because of its large mass, has a 
great capacity for l,25(OH)2D3-mediated induction of 24-OHase activity (Kumar et al., 
1978). It also has been demonstrated in intestine, as contrasted with kidney, that endogenous 
increases in plasma l,25(OH)2D3 concentrations stimulate induction of intestinal 24-OHase 
[I-24-OHase] activity (Goff et al., 1992; Shinki et al., 1992). 
The present study examines the interaction between low dietary Ca and vitamin D3 
excess on the MCR of both 25-OH-D3 and l,25(OH)2D3. We demonstrate the importance 
of MCR measurements in interpreting plasma l,25(OH)2D3 concentrations particularly 
under conditions of excessive dietary vitamin D3 and discuss its importance in potentiation 
of 1,25(0H)2D3 action in target tissues. 
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MATERIALS AND METHODS 
Chemicals 
Vitamin D3 was purchased from Sigma Chemical (St. Louis, MO). Vitamin D3 
metabolite standards were generous gifts from Milan Uskokovic (Hoffmann-LaRoche, Inc., 
Nutley, NJ). All solvent used in vitamin D metabolite extraction was reagent grade and 
purchased from Burdick and Jackson (Muskegan, ML) or Fisher Scientific (Fairlawn, NJ). 
HPLC was with a Waters AlGpC 204 liquid chromatograph fitted with a Model 810-A 
Waters intelligent sampling processor (WISP 810-A). Preparation of 25-0H-[3H]-D3 (80 
Ci/mmol) and 1,25(0H)2[3H]-D3 (80 Ci/mmol) was by the method of Napoli et al. (1980). 
The purification of labeled metabolites was in normal straight phase on Dupont Zorbax Silica 
(Wilmington, DE) HPLC columns. Sep Paks used in the study were bought from Waters 
Associates, Inc. (Milord, MA). Radioactivity was measured in a Beckman LS-7800 
scintillation counter. 
Animals and Diets 
Three-week-old male weanling rats (Harlan Sprague-Dawley) were fed a purified 
vitamin D3-sufficient, adequate Ca diet (Teklad, Madison, WI; 1.0% Ca and 0.3% 
phosphorus) for 2 weeks. At five weeks of age, half of the rats were switched to a vitamin 
D3-sufficient, low Ca diet (0.02% Ca and 0.3% phosphorus). At six weeks of age, half of the 
rats from each of the two groups were given orally 25,000 lU (625 mg) of vitamin D3/2OO |il 
corn oil 3 times per week for a total of 8 doses, and the other half of the rats were given 
placebo at each administration. At the end of the administration period the rats were 
rendered unconscious with C02:02 (50:50), then euthanized by decapitation. Blood was 
collected into tubes containing heparin and centrifuged the at 1500 x g for 30 min at 4 °C to 
obtain plasma. 
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Determination of MCR and PR 
Quantification of 25-OH-D3 MCR and l,25(OH)2D3 MCR was by a modification of 
the equilibrium infusion method of Tait et al. (1962). For 25-OH-D3 MCR, rats were 
implanted on the interim day between the second and third dose of vitamin D3 with 14-day 
(model 2002) osmotic minipumps (Alza, Palo Alto, Ca). For l,25(OH)2D3 MCR, rats were 
implanted on the interim day between the fifth and sixth dose of vitamin D3 with 7-day 
(model 2001) osmotic minipumps. Before implantation, rats were injected with 80 mg/kg of 
ketamine hydrochloride (Ketaset) and kept lightly anesthetized with isoforane. For pump 
loading, the vitamin D3 [3H]-metabolites were in a solvent of 1.25% ethanol in propylene 
glycol. Infusion rates of model 2002 and model 2001 pumps were 12 and 24 ml/d, 
respectively. Delivery rates of 25-OH-D3 and l,25(OH)2D3 were calibrated to approximate 
100 and 125 dpm/min, respectively. These rates of labeled metabolite infusion were <1.0% 
of the endogenous production rates. An initial trial showed that 1,25(0H)2-[3H]-D3 reached 
steady-state with plasma pools within three days of infusion. According to work of Halloran 
and Castro (1989), steady-state for 25-0H-[3H]-D3 is difficult to achieve, even within a two-
week period. Therefore, 25-0H-[3H]-D3 was infused for two weeks beginning after the 
second dose of excess vitamin D3 and was continued to the end of the study. By definition 
MCR is the volume of blood cleared completely and irreversibly of a specific substance per 
unit time and is equal to plasma labeled metabolite concentration (Tait et al., 1962). The 
calculation of MCR (ml x min'l x kg'l ) was by the following equation: [(infusion rate 
dpm/min) / (steady-state plasma [3H]-metabolite concentration dpm/ml)] times kg body 
weight. The production rate (PR) relates to MCR by the following equation: PR (pg x min'^ 
X kg body wt"l ) = MCR (ml x min'l x kg body wf^ ) x plasma metabolite concentration 
(pg/ml), (Tait, 1963). 
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Determination of Plasma and Urine Ca and Creatinine Clearance 
Quantification of plasma and urine calcium concentrations was by atomic absorption 
spectrophotometry using a Perkin Elmer 5000-AA system (Perkin-Elmer Corporation, 1965). 
For urine collections, rats were kept individually in metabolic cages for a 24-hr period just 
before the termination of the experiment and made urine collections at 8-hr intervals (4 
collections). The rats had clean water and fresh food throughout the 24-hr collection period. 
At each collection, total urine volume was recorded and approximately 2 ml of urine was 
transferred to storage tubes and froze the at -20 °C. Quantification of plasma and urine 
creatinine was by absorbance of the red pigment, alkaline creatinine picrate (Jaffe reaction) at 
520 nm. Briefly, 10 |il aliquots of plasma (not diluted) or urine (1:10 dilution) were mixed 
with 200 111 of alkaline picrate (190 ml of 0.04 M picric acid; 10 ml 3 N NaOH). The 
reaction was allowed to proceed at room temperature for 30 min, and then compared to a 
reagent blank of distilled water at 520 nm. Creatinine standards ranged in serial dilution 
from 0-80 mg/dl. Creatinine clearance (ml/min) equaled [(urine volume ml/min) x (urine 
creatinine mg/dl)] / [(plasma creatinine mg/dl)]. 
Analysis of Plasma Metabolite Concentration 
Separate groups of rats fed the same diets and treatments as previously described 
were used to quantify 1,25(OH)2D3 MCR and 25-OH-D3 MCR, respectively. Therefore, 
extraction and HPLC purification of the vitamin D3 metabolites were attained from 
independent samples of plasma. In the case of 1,25 (OH) 2D 3, quantification of 
1,25(0H)2[3H]-D3 was by the following method. Approximately 100 ng of nonradiolabeled 
1,25(0H)2D3 was added to 2-3 ml of plasma. Following extraction with 1 volume of 
acetonitrile, the extracts were applied to C-18 Sep-Pak (Waters Associates, Milford, MA) 
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cartridges. The eluted fraction was dried and redissolved in isopropanohhexane (4:96, v/v) 
and subjected to silica Sep-Pak chromatography. Silica columns were washed with 5 ml of 
isopropanohhexane (6:94, v/v), and l,25(OH)2D3 was eluted in 9 ml of isopropanohhexane 
(15:85, v/v). This fraction then was chromatographed on a 5 mm cyano column (ISCO Inc., 
Lincoln, NE) equilibrated in a quaternary solvent system of acetonitrile:ethanol:methylene 
chloride:hexane (1.0:3.5:6.5:89, v/v/v/v) at a flow rate of 2.0 ml/min. The l,25(OH)2D3 
fraction from the cyano column was dried under nitrogen, and the amount of 3h was 
determined by scintillation counting. For quantification of plasma l,25(OH)2D3, 1 ml of 
plasma was extracted and purified by HPLC. For determination of recovery, enough 
1,25(0H)2[3H]-D3 was added to samples before extraction to bring the total counts of each 
sample to about 1000 cpm/ml. Concentrations of 1,25(0H)2D3 in HPLC fractions were 
calculated by binding assay (Reinhardt et al., 1984). 
Serum 25-0H-[3H]-D3, 25-OH-D3, and 24,25(OH)2D3 quantification was done by 
the following procedures. One hundred ng of 25-OH-D2 and 1000 cpm/ml of 
24,25(0H)2[3H]-D3 were added to 2 ml of plasma to monitor recoveries of 25-OH-D3 and 
24,25(0H)2D3, respectively. The extracted samples were applied to C-18 columns. The 
eluted samples were dried, redissolved in 0.5 ml isopropanohhexane (1:99, v/v), applied to 
silica Sep-Paks, and washed with an additional 10 ml of isopropanohhexane (1:99, v/v). The 
25-OH-D3 fraction was eluted with isopropanohhexane (4:96, v/v), and the 24,25(OH)2D3 
fraction was eluted with isopropanohhexane (10:90, v/v). The 25-OH-D3 eluate was applied 
to a 5 mm amino column (ISCO Inc., Lincoln, NE) developed in isopropanol:methylene 
chloride:hexane (2:10:88, v/v/v) at a flow rate of 2.0 ml/min. The 24,25(0H)2D3 eluate was 
applied to a 5 mm cyano column prepared in a solvent system of 
acetonitrile :ethanol : methylene chloride:hexane (1.0:2.5:5.5:91, v/v/v/v). Similar to 
measurement of plasma 1,25(0H)2[3H]-D3, the fractions from the 5 mm amino column 
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corresponding to 25-OH-D3 were collected in scintillation vials, dried under nitrogen, and 
counted in a Beckman LS7800 scintillation counter to determine amount of 3h. 
Quantification of 25-OH-D3 and 24,25(OH)2D3 was by absorbance at 254 nm. 
Statistics 
The Student-Newmann-Keuls multiple range test was used to determine significant 
differences between control and treated groups. 
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RESULTS 
Illustrations of 25-OH-D3 PR and 25-OH-D3 MCR as influenced by both dietary Ca 
and vitamin D3 status are shown in Figure 1. The 25-OH-D3 PR of NC rats was 2.3 ± 0.5 pg 
X min-1 xkg-l (Figure lA). The NCT treatment increased the 25-OH-D3 PR by 40.0-fold 
(91.4 ± 15.0 ng X min-1 x kg'^ ) over that of NC rats. In LC rats, 25-OH-D3 PR decreased by 
78% (0.5 ± 0.1 ng X min-1 x kg'l ), while excess vitamin D3 treatment to LCT rats, caused a 
17.4-fold increase in 25-OH-D3 PR (39.8 ± 9.8 ng x min-^ x kg'^ ) 
The estimated 25-OH-D3 MCR (Figure IB) of NC rats was 19.3+1.9 ml x min'l x 
kg'l. In NCT rats 25-OH-D3 MCR increased by 2.6-fold (50.2 ± 6.2 ml % min'l x kg"l ) as 
compared to 25-OH-D3 MCR of NC rats. The 25-OH-D3 MCR of LC rats decreased by 
20% (15.6± 1.9 mix min"! xkg"l), but this decrease was not significant. In LCT rats, there 
was a 1.5-fold increase in 25-OH-D3 MCR (28.3 ± 3.2 ml % min"l x kg'l ), but this increase 
was 48% less than the increase in NCT rats, (P <0.01). 
Figure 2 depicts l,25(OH)2D3 PR and l,25(OH)2D3 MCR in response to dietary Ca 
and vitamin D3 status. The l,25(OH)2D3 PR (Figure 2A) of NC rats was 37.4 pg x min-1 x 
kg'l. In NCT rats, l,25(OH)2D3 PR increased by 3.0-fold (114.2 ± 21.8 pg x min- ^ x kg"l P 
<0.01), and, in both LC and LCT rats, l,25(OH)2D3 PR increased by about 6.0-fold each 
(LC, 209.3 ± 35.8 pg x min- ^  x kg"l and LCT, 232.4 ± 35.8 pg x min- ^  x kg"l' P <0.001). 
The estimated l,25(OH)2D3 MCR (Figure 2B) of NC rats was 359.7 ± 44.6 ml x 
min-1 xkg-1. The l,25(OH)2D3 MCR of NCT rats increased by 3.5-fold (1270.9 ± 225.9 ml 
X min"^ xkg-1). Despite the very high PR of 1,25(OH)2D3 in LC rats, the MCR of 
1,25(0H)2D3 in these rats did not increase significantly (455.0 ± 17.5 ml x min'^ xkg"l ). 
Finally, the MCR of l,25(OH)2D3 in LCT rats increased by 3.8-fold (1378.6 ± 145.6 ml x 
min'l xkg"^ ), which was an increase of 380% (P <0.001), indicating that a great capacity for 
extrarenal clearance of l,25(OH)2D3 exists in rats. 
30 
Plasma and urine Ca concentrations were good indicators of the vitamin Dg status of 
the rats in this study (Table 1). Dosing of excess vitamin Dg in NCT rats caused 
hypercalcemia and hypercalciuria. In contrast, dietary Ca restriction in LC rats caused low 
plasma Ca concentration. In LCT rats, the low Ca status was reversed partially. Restriction 
of urinary Ca excretion occurred in both LC and LCT rats. As compared with NC rats, all 
treatment groups (NCT, LC, and LCT rats) showed small increases in creatinine clearance. 
While the cause of this increase was uncertain, an increase in creatinine clearance does not 
indicate renal dysfunction. 
Table 2 profiles concentrations of the three most prevalent plasma vitamin D3 
metabolites in response to dietary Ca restriction and vitamin D3 toxicity. Plasma 25-OH-D3 
concentration increased greatly in NCT rats, 16.9-fold (P <0.001), compared to plasma 25-
OH-D3 concentration in NC rats. In contrast, Ca restriction in LC rats decreased plasma 25-
OH-D3 concentration by 50% (P <0.01) compared to NC rats. A similar 60%, (P <0.01) 
reduction of plasma 25-OH-D3 concentration also occurred in LCT rats as contrasted with 
plasma 25-OH-D3 concentration in NCT rats. 
The profile of plasma 24,25(OH)2D3 concentrations was similar to that for 25-OH-
D3. In NCT rats, plasma 24,25(OH)2D3 concentration increased by 27.4-fold, and, in LC 
rats, plasma 24,25(OH) 2D3 concentration was not detectable. The LCT treatment increased 
plasma 24,25(OH)2D3 concentration by 14.2-fold (P <0.001); however, the augmentation 
was only 50% of plasma 24,25(OH)2D3 concentration in NCT rats. 
Also profiled in Table 2 are plasma l,25(OH)2D3 concentrations. In NCT rats, 
plasma l,25(OH)2D3 concentration did not change significantly as compared with plasma 
l,25(OH)2D3 concentration in NC rats. In contrast, plasma l,25(OH)2D3 concentration 
increased by 6-fold (P <0.001) in LC rats, but in LCT rats, the increase in plasma 
1,25(0H)2D3 concentration was only 1.8-fold. 
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DISCUSSION 
By our methods, l,25(OH)2D3 MCR was -360 ml x min"^ x kg'l, which is similar to 
what others have reported for growing rats (Hsu et al., 1987; Halloran and Castro, 1989), and 
was about 20 times the rate of clearance observed for 25-OH-D3 (Figure 2A). To date, there 
is an incomplete understanding of the mechanisms modulating l,25(OH)2D3 MCR. Studies 
in rats with renal failure indicate that the kidney accounts for one third or more of total 
1,25(0H)2D3 MCR (Hsu et al., 1987), and much of this MCR occurs through the C-24, C-
23-pathway. A comparison of kidney and intestinal 24-OHase activities has demonstrated 
that the kidney is the predominant site of 24-OHase activity when plasma Ca concentrations 
are normal (Shinki et al., 1992). Low plasma Ca concentrations stimulate increased blood 
PTH, which blocks 1,25(0H) 2D3-mediated induction of 24-OHase in kidney (Shigematsu et 
al., 1986). Unlike kidney, the intestine has not been found to posses PTH receptors, and 
endogenous increases in l,25(OH)2D3, produced in response to Ca restriction, presumably 
lead to sustantially increased I-24-OHase activity (Shinki et al., 1992; Goff et al., 1992). 
The interpretation of 1,25 (OH) 2D 3 MCR must take into account the sum of all 
1,25(0H)2D3 inactivation occurring at various tissue sites, regulation of tissue-specific 
1,25(0H)2D3 inactivation, and the influence of specific factors regulating the 1,25(0H)2D3 
MGR. Chronic l,25(OH)2D3 administration causes an increase in l,25(OH)2D3 MCR and 
that of other vitamin D3 metabolites (Halloran and Castro, 1989). Conversely, prolonged 
plasma l,25(OH)2D3 half-life occurs in rats deficient in l,25(OH)2D3 (Jongen et al., 1987), 
and, in simple vitamin D deficiency, an enhancement in l,25(OH)2D3 MCR of intravenously 
dosed 1,25(0H)2[3H]-D3 occurs (Frolick and DeLuca, 1973). The study of Favus and 
Langman (1984) likewise showed that the increase of 1,25(0H)2D3 MCR in response to 
subcutaneous 1,25(OH) 2D3 administration is greater in vitamin D3-deficient rats compared 
with vitamin D3-replete counterparts. Collectively, these studies suggest that l,25(OH)2D3 
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mediates increases in the MCRs of l,25(OH)2D3 and other vitamin D3 metabolites, thereby 
initiating feedback regulation on plasma l,25(OH)2D3 concentrations. 
The present study, like those of Paulson and Kenny (1985) and Jongen et al. (1987) 
but unlike the study of Fox et al. (1990), showed that, whereas plasma l,25(OH)2D3 
concentration increased by 4.3-fold in LC rats, l,25(OH)2D3 MCR remained constant. The 
question is, how do 1,25(OH)2D3 MCR and l,25(OH)2D3 PR in LC rats become 
uncoupled? One explanation might be that because plasma l,25(OH)2D3 concentration 
increases during hypocalcemia, the increased rate of l,25(OH)2D3 formation exceeds 
1,25(0H)2D3 MCR, and the specific radioactivity of the tracer (l,25(OH)2[^H]-D3) would 
dilute out, indicating nonsteady-state. The implication being that the use of MCR and PR 
equations for l,25(OH)2D3 may be invalid if the assumed steady state does exist. This 
implication would debunk several published studies that have applied mathematical 
equations for measuring l,25(OH)2D3 MCR and PR. 
Alternatively, the uncoupling of l,25(OH)2D3 MCR and l,25(OH)2D3 PR in LC rats 
could be the result of a buffering action by plasma vitamin D binding protein (DBP). In 
other words, the decreases in plasma 25-OH-D3 and 24,25(OH)2D3 concentrations during 
Ca restriction might have increased l,25(OH)2D3 binding with plasma DBP. In contrast, 
plasma 25-OH-D3 and 24,25(OH) 2D3 concentrations of NCT and LCT rats were increased 
greatly, which could have caused 1,25(OH) 2D3 displacement from DBP and augmentation of 
free l,25(OH)2D3 concentration. Free plasma l,25(OH)2D3 has a greater potential 
biological action than DBP-bound plasma 1,25(OH)2D3 (Boullion and van Baelen, 1981). 
Increased displacement of l,25(OH)2D3 from DBP likely would potentiate an increase in 
1,25(0H)2D3 MCR, as occurred, for example, in NCT and LCT rats. The 40.0-fold increase 
in 25-OH-D3 PR in NCT rats as contrasted with only a 2.6-fold increase in 25-OH-D3 MCR 
in NCT rats is a profound indication that a plasma DBP reservoir buffers the effect of 25-OH-
33 
D3 as an agent of vitamin D3 toxicity. As the plasma DBF capacity for 25-OH-D3 binding 
exceeds the natural limit, 25-OH-D3 catabolism also would increase. 
A recent proposal by Vieth (1990) contends that l,25(OH)2D3 is the causative agent 
of vitamin D3 toxicity instead of 25-OH-D3^ as others have suggested (Hughes et al., 1976). 
Vieth maintains that during vitamin D3 toxicity the amount of free l,25(OH)2D3 increases, 
that there is increased extrarenal l,25(OH)2l>3 production, and that there is insufficient 
1,25(0H)2D3 MCR to handle the excess production of l,25(OH)2D3. That the latter can 
occur is evidenced by our data in LC rats showing that l,25(OH)2D3 PR increased by 5.6-
fold, while l,25(OH)2D3 MCR did not increase at all. 
The lower affinity of l,25(OH)2D3 for plasma DBF, relative to other metabolites of 
vitamin D3, increases the potential for l,25(OH)2D3 displacement from plasma DBF greatly 
during vitamin D3 toxicity. In addition, lactone metabolites of vitamin D3, generated from 
excessive dietary vitamin D3, possess five times greater affinity than 25-OH-D3 for plasma 
DBF (Horst, 1979). We have studied renal la-OHase activity in NCT rats (data not 
presented) and have found that NCT treatment causes a significant decrease in la-OHase 
activity. Therefore, the increase in l,25(OH)2D3 FR in NCT rats, despite the decrease in 
renal 1 a-OHase activity, may be evidence for extrarenal la-OHase activity in association 
with excessive dietary vitamin D3. Bone is one extrarenal tissue thought to be capable of 1 a-
hydroxylation (Howard et al., 1981), and there may be others as well. Furthermore, even 
though 25-OH-D3 and l,25(OH)2D3 MCRs both increased markedly in NCT rats, so did the 
FRs of these metabolites. 
The final interpretation of MCR effects on plasma l,25(OH)2D3 concentrations must 
take into account potential tissue-specific regulation of inactivation pathways of vitamin D3. 
The essential feature of vitamin D3 toxicity is hypercalcemia, which is caused by 
uncontrolled intestinal calcium absorption. The present study showed that dietary Ca 
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restriction can reverse the toxicity of excess vitamin Dg as was demonstrated by low plasma 
and urine Ca concentrations in these rats. As mentioned earlier, the intestine may represent 
an important tissue in the inactivation of l,25(OH)2D3. At the same time, the intestine is an 
important target tissue of l,25(OH)2D3 action. During Ca restriction, induction of 24-
hydroxylase (Goff et al., 1992) and l,25(OH)2D3 action (Friedlander et al., 1977) both 
increase, however, VDR undergoes very little change (Goff et al., 1990), which indicates that 
intestinal Ca absorption correlates more closely with l,25(OH)2D3 PR than changes in VDR. 
In vitamin D3 toxicity, l,25(OH)2D3 PR may exceed the ability of the intestine to effectively 
control local stimulation of l,25(OH)2D3 action, and this coupled with an increase in 
intestinal VDR concentration may explain intestinal hypersensitivity. 
In summary, l,25(OH)2D3 MCR was not influenced by the increase in l,25(OH)2D3 
PR, induced by dietary Ca deficiency, in LC rats. Moreover, significant increases in 
1,25(0H)2D3 PR and l,25(OH)2D3 MCR in LCT rats suggest substantial induction of 
extrarenal 24- and la-hydroxylase activity, which could profoundly affect l,25(OH)2D3 
action in extrarenal tissues such as intestine. 
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Figure 1. A) Production rates and B) metabolic clearance rates of 25-OH-D3. 
Means ± SEM are presented (n=6-8 rats in each group). * = P <0.05; ** = P 
<0.01; *** = P<0.001; significant difference between NCT, LC, or LCT groups 
versus NC group, t = P < 0.01; significant difference between LCT group 
versus NCT group. 
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Figure 2. A) Production rates and B) metabolic clearance rates of l,25(OH)2D3. 
Means ± SEM are presented (n=6-8 rats in each group). ** = p <0.01; *** = 
P<0.001; significant difference between NCT, LC, or LCT groups versus NC 
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Table 1. Changes in plasma Ca, urine Ca, and rate of creatinine clearance in response to dietary Ca restriction and vitamin 
D3 excess ^  
Plasma Ca Urine Ca Creatinine clearance 
Treatment (mg/dl) (mg/d) (ml/min) 
NC 10.68 ±0.17 2.62 ±0.67 0.35 ±0.04 
NCT 12.58 ± 0.33 *** 40.10 ± 4.81*** 0.46 ±0.01* 
LC 9.69 ±0.19* 1.06 ±0.31* 0.42 ±0.04 
LCT 10.45 + 0.15 Î 0.48 ± 0.06 **, t 0.49 ±0.03* 
^Values are means ± SEM (n=8). NC, 1.0% Ca; NCT, 1.0% Ca plus 25,000 lU D3 (3 times/wk), LC, 
0.02% Ca; LCT 0.02% Ca plus 25,000 lU D3 (3 times/wk). Significant differences were measured by the 
Student-Newmann-Keuls multiple range test. 
* significant difference at P <0.05 versus NCT group 
** significant difference at P <0.01 versus NCT group 
*** significant difference at P <0.001 versus NCT group 
t significant difference at P <0.001 versus NCT group 
Table 2. Changes in plasma vitamin D3 metabolite concentrations in response to dietary Ca restriction and vitamin D3 
excess ^ 
25-OH-D3 24,25(0H)2D3 1,25(0H)2D3 
Treatment (ng/ml) (ng/ml) (pg/ml) 
NC 107.5 ± 16.4 2.6 ± 0.6 106.3 ± 18.7 
NCT 1812.6 ± 164.5 *** 71.3 ± 10.3 *** 96.0 ± 12.3 
LC 46.5 ± 10.4 ** NDb 459.0 ± 70.4 *** 
LCT 1129.8 + 62.3 ***, t 36.9 ± 6.1 **,¥ 187.6 ± 41.1, V 
^Values are means ± SEM (n=6-8). NC, 1.0% Ca; NCT, 1.0% Ca plus 25,000 lU D3 (3 times/wk), LC, 
0.02% Ca; LCT 0.02% Ca plus 25,000 lU D3 (3 times/wk). Significant differences were measured by the Student-Newmann-
Keuls multiple range test. 
^ND not detected 
** significant difference at P <0.01 vs. NCT group 
*** significant difference at P <0.001 vs. NCT group 
t significant difference at P <0.001 vs. NCT group 
¥ significant difference at P <0.05 vs. NCT group 
V significant difference at P <0.05 vs. LC group 
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ABSTRACT 
In previous studies, we demonstrated that calcium restriction caused down-regulation 
of kidney 1,25-dihydroxyvitamin D3 receptors (VDR) and blocked 1,25(OH) 2D 3-mediated 
up-regulation of intestinal VDR. Studies in our laboratory have linked parathyroid hormone 
(PTH) with this regulation. We examined further the factors regulating in vivo VDR 
concentration and l,25(OH)2D3 target tissue responsiveness by the interaction of dietary 
calcium (Ca) restriction and excess vitamin D3 (75,000 lU /wk). Plasma PTH concentration 
was lowered to about 45 pg/ml either by feeding rats diets containing 1.0-1.2% Ca and 
normal vitamin D3 (NC) or NC diet containing excess vitamin D3 (NCT). The NCT 
treatment resulted in up-regulation of intestinal VDR by 70% but caused only a modest 
increase in intestinal 24-OHase activity by 2.8-fold. In contrast, Ca restriction alone (LC) 
blocked intestinal VDR up-regulation but increased intestinal 24-OHase activity by 12-fold. 
Furthermore, the combination of excess vitamin D3 treatment and Ca restriction (LCT) 
limited the up-regulation of intestinal VDR concentration to an increase of only 36% (1.3-
fold) but resulted in a dramatic 44.4-fold increase in intestinal 24-OHase mRNA expression 
and 26-fold increase in activity. Nutritional hyperparathyroidism, caused by dietary Ca 
restriction, was assosiated with a decrease in kidney responsiveness to LCT treatment or 
endogenous increase in l,25(OH)2D3 of LC rats as indicated by a reduction of vitamin D3-
dependent gene expression of 24-hydroxylase (24-OHase) by 66%, VDR by 30%, calcium 
binding protein-28k (CaBP-28k) by 20%, down-regulation of kidney VDR concentration, 
and inhibition of kidney 24-OHase activity. In conclusion, the data indicate differential 
responsiveness to l,25(OH)2D3 action in kidney versus intestinal tissues. 
46 
INTRODUCTION 
The active metabolite of vitamin D3, l,25(OH)2D3, is similar to steroid hormones in 
that it binds with high affinity to specific and saturable intracellular receptors present in 
target tissues (Haussier et al., 1988). The binding of l,25(OH)2D3 to VDR confers 
transcriptional activity, whereby the 1,25(OH) 2D 3-VDR complex influences the expression 
of several vitamin D3-dependent genes and mediates the cellular and metabolic actions of 
1,25(0H)2D3 (Minghetti and Norman, 1988). The study of VDR regulation in target tissues 
is important because it relates to the cellular actions mediated by l,25(OH)2D3 in such 
physiological states as early growth and development, pregnancy, lactation, aging, and 
dietary Ca restriction (Halloran and DeLuca, 1981; Horst and Reinhardt, 1988; Goff et al., 
1988; Horst et al., 1990; and Goff et al., 1990). Collectively, these in vivo studies suggest 
that target cell responsiveness to l,25(OH)2D3 is directly proportional to target cell VDR 
concentration, as has been shown in vitro (Costa et al., 1985). In addition, several other 
hormones including estrogen, glucocorticoids, and retinoic acid (Walters, 1981; Hirst and 
Feldman, 1982; Petkovich et al., 1984) may effect changes in target tissue VDR 
concentrations and, therefore, may play adjunct roles in modulating tissue responsiveness to 
1,25(0H)2D3. 
Costa and Feldman (1986) demonstrated that pharmacological 1,25(0H)2D3 
administrations to rats stimulate up-regulation of VDR in the major target tissues of intestine, 
kidney, and bone, and, likewise, homologous up-regulation of VDR occurs in cultured cells 
(Costa et al., 1985; Chen et al., 1986; McDonnell et al., 1987). These early studies 
describing homologous VDR up-regulation have advanced the theory that 1,25(0H)2D3 
enhances its own target cell responsiveness through a positive feed-forward type mechanism. 
The understanding that 1,25 (OH) 2D 3 induces VDR and several other vitamin D-dependent 
genes such as 24-OHase, calbindin-28k ( CaBP-28k), and calbindin-9k (CaBP-gk) in the 
major target organs of vitamin D is thoroughly reviewed by Lowe et al. (1992). However, 
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the expression of these well-known actions of l,25(OH)2D3 depends on the physiological 
condition of the animal, and l,25(OH)2D3 action may also be influenced by hormonal and 
local tissue-specific factors. 
Several studies demonstrate the tissue-specific nature of 1,25(OH) 2D3 
responsiveness. Exogenous l,25(OH)2D3 administration potentiates induction of 24-OHase 
in many vitamin D3 target tissues (Haussier et al., 1988), and, in some of these tissues, 
induction of 24-OHase by l,25(OH)2D3 may cause self-induced catabolism thus limiting 
1,25(0H)2D3 action (Reinhardt and Horst, 1989a). Kidney and bone, unlike intestine, 
possess parathyroid hormone (PTH) receptors (Coltrera et al., 1981; Shigeno et al., 1988). 
An increase in plasma PTH concentration inhibits renal 24-OHase activity while stimulating 
la-OHase activity (Shigematsu et al., 1986). Initial experiments in bone and intestine, 
however, demonstrate no inhibition of 24-OHase by PTH (Nishimura et al., 1992; Shinki et 
al., 1992). In theory, there should be an enhancement in tissue response to 1,25(OH)2D3 
during hypocalcemic conditions because blood l,25(OH)2D3 increases. In contrast, Goff et 
al. (1990) showed that dietary Ca restriction in rats, despite endogenous increases in 
1,25(0H)2D3 concentration to > 800 pg/ml, blocked intestinal VDR up-regulation and 
decreased kidney VDR significantly. Reinhardt and Horst (1990) treated ROS 17/2.8 cells 
with PTH (0-5 nM) and observed a dose- and time-dependent decline in VDR and VDR 
mRNA. Down-regulation of kidney and intestine VDR by PTH also was produced in vivo by 
coinfusing l,25(OH)2D3 and PTH into rats versus infusing l,25(OH)2D3 alone. Because the 
intestine is not a PTH target organ, we considered the possibility that independent 
mechanisms control VDR regulation in kidney versus intestine. 
In addition to the genes encoding VDR and 24-OHase, the gene for calcium binding 
protein (CaBP) can be induced by l,25(OH)2D3, therefore CaBP was used in the present 
study as another marker of vitamin D3 and l,25(OH)2D3 action in kidney and intestine. The 
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results of this study demonstrate differential regulation of l,25(OH)2D3 action in kidney 
versus intestine tissues. 
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MATERIALS AND METHODS 
Diets and Animals 
All diets were bought from Teklad (Madison, WL). Male Sprague-Dawley rats 
(Madison, WI) 21 d of age ate a purified vitamin D-deficient diet containing 0.5% Ca for 
three wk before being fed the experimental diets. The rats were repleted with a total of 300-
600 lU of vitamin Dg orally per wk. At 6 wk of age, the rats were arranged randomly into 
four groups, with two groups receiving a vitamin D-deficient, normal Ca (1.0-1.2%, 
designated NC) diet, and two groups receiving a vitamin D-deficient, low Ca (0.02%, 
designated LC) diet. The rats were given 1 wk to adapt to these diets; then, one group from 
each diet received excess vitamin Dg at the rate of 25,000 lU three times per wk for a total of 
75,000 lU/wk (1875 (ig). The groups receiving the excess vitamin Dg were designated NCT 
and LCT. All other rats continued receiving supplemental vitamin Dg. The period of excess 
vitamin Dg treatment lasted for 2.5 wk (8 doses). 
Plasma Ca, PTH, and Vitamin D3 Metabolites 
At the end of the experiment, the rats were rendered unconscious with C02-02 
(50:50, v/v) and decapitated. Blood was collected into tubes containing heparin. Blood was 
centrifiiged the at 1500 x g for 30 min at 4 °C to obtain plasma. The plasma was analyzed for 
Ca, vitamin Dg metabolites, and PTH concentrations. Plasma Ca concentration was 
measured by atomic absorption spectrophotometry (Perkin-Elmer Corporation, 1965). 
Plasma 25-OH-Dg, 24,25(OH)2Dg, and 1,25 (OH) 2D g were extracted and quantified by 
using previously described techniques (Horst et al., 1981; Reinhardt and Horst, 1988); 
exceptions are noted below. Plasma PTH was quantified by using an N-terminal specific 
RIA kit from Nichols Institute (San Juan Capistrano, CA). 
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Intestinal and Kidney VDR Assay 
For quantification of intestinal VDR, a 15-cm section of the proximal duodenum was 
removed and rinsed with 10 ml of Tris-buffered saline (10 mM Tris and 150 mM NaCl, pH 
7.2) containing 100,000 units of Trasylol (Mobay Chemical Corp., New York, NY) and then 
scraped with glass slides and separated the mucosal cells. All subsequent steps were carried 
out at 4°C. A portion of the mucosal cells was stored at -20°C for subsequent 24-OHase 
activity assay. Another portion was quick-frozen in liquid nitrogen for later uses in mRNA 
studies. For the I-VDR assay, the rest of the mucosa cells was put into 3 ml of TED (50 mM 
Tris, 1.5 mM EDTA, and 2.0 mM dithiothreitol) buffer containing 200 mg/L soybean trypsin 
inhibitor, and centrifuged at 5,000 x g for 5 min at 4°C. Twenty percent homogenates were 
prepared from each sample in KTED (600 mM KCl plus TED) buffer containing 200 mg/L 
soybean trypsin inhibitor. Each sample was homogenized (Brinkmann Instruments Polytron, 
Westbury, NY) for two 15-second bursts at a setting of 8 and cooled between bursts. The 
homogenates were centrifuged at 110,000 x g for 20 min by using an L8-80 M ultracentrifuge 
(Beckman Instruments, Palo Alto, CA). 
The cytosol supernatant was collected and assayed for intestinal VDR concentration. 
The receptor assay was set-up in six tubes per sample by adding 8 nM l,25(OH)2[26,27-
methyl-^Hj-Dg (80 Ci/mmol; Napoli et al., 1980) to 60-|il aliquots of cytosol. To three of 
the tubes, we added 480 nM of unlabeled l,25(OH)2D3 for determination of nonspecific 
binding. The total volume was brought to 0.5 ml with 300 mM KCl. The assay was 
incubated for 16 h at 4°C. Receptor-bound 1,25(OH) 2D3 was separated from free 
1,25(0H)2D3 by hydroxylapatite (Wecksler and Norman, 1979). We calculated specific I-
VDR binding by subtracting nonspecific-bound 1,25(0H)2[^H]-D3 from total-bound 
1,25(0H)2[^H]-D3. All VDR data were expressed as fmol of VDR/mg protein in cytosol. 
Cytosolic protein concentrations were determined by the method of Bradford (1976). The 
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quantification of kidney VDR was similar to that of the intestine, except that we minced the 
kidney tissue before it was homogenized. 
Kidney 1 a- and 24 -Hydroxylase Assays 
For quantification of kidney 1 a-OHase (K-la-OHase) activity, the renal slice method 
described by Armbrecht et al. (1982) was used. Briefly, kidney slices were prepared by using 
a Stadie-Riggs microtome to produce thin slices of 70-100 mg apiece. The slices were placed 
in preweighed 15-ml flasks with 1ml of Krebs-Ringer bicarbonate buffer containing 1 mg/ml 
glucose, and 1 mg/ml bovine serum albumin. The buffer was pregassed for 30 min with 
02:C02 (95%:5%, v/v). The K-la-OHase reaction was initiated by adding 2 |ig of 25-OH-
D3 to each reaction flask (5 |iM final concentration). Flasks were flushed quickly with 
02:C02 (95%:5%, v/v), stoppered, and incubated in a shaking water bath (-60 cycles/min) 
for 1 hr at 37°C. The reaction was terminated by adding 1 ml of acetonitrile to each reaction 
vessel. Then, 3 ml of water per sample were added, and the samples were homogenized by 
using a Dounce homogenizer (20 strokes). Sample recovery was monitored with 1000 cpm 
1,25(0H)2[3H]-D3. Samples were extracted with 3 ml of acetonitrile followed by 
centrifugation at 1500 x g for 15 min using a Beckman Model J-6M centrifuge (Beckman 
Instruments). 
The HPLC methodology of Armbrecht et al. (1982) was modified to avoid 
comigration of l,25(OH)2D3 with 19-nor-10-oxo-25-OH-D3. Following extraction, samples 
were applied to C-18 Sep-Paks (Waters Associates, Milford, MA). The eluates were dried 
and redissolved in isopropanol:hexane (4:96, v/v) and applied to silica Sep-Paks. Silica 
columns were washed with 5 ml of isopropanol:hexane (6:94, v/v), and l,25(OH)2D3 was 
eluted in 9 ml of isopropanol:hexane (15:85, v/v). This fraction then was chromatographed 
onto a 5|xm shperisorb packed cyano column (ISCO Inc., Lincoln, Nebraska) developed in a 
quaternary solvent system of acetonitrile : ethanol : methylene chloride:hexane (1.0:3.5:6.5:89, 
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v/v/v/v) at a flow rate of 2.0 ml/min. Concentrations of l,25(OH)2D3 from HPLC fractions 
were determined by binding assay (Reinhardt et al., 1984). The K-la-OHase activity was 
e x p r e s s e d  a s  p g  o f  l , 2 5 ( O H ) 2 D 3  p r o d u c e d  x h r ' l  x m g  t i s s u e .  
Kidney 24-OHase (K-24-OHase) activity was quantified according to procedures 
developed by Engstrom et al (1984). Briefly, kidney tissue was minced into small pieces 
and prepared as a 10% homogenate in a 0.2 M sucrose buffer. Aliquots of 2 ml of 
homogenate (200 mg tissue) incubated for 30 min with 2 )J.g of 25-OH-D3 substrate (2.5 [iM 
final concentration). For analysis of K-24-OHase activity, 24,25(OH)2D3 product was 
extracted and purified by HPLC as previously described (Reinhardt and Horst, 1988) and 
quantified by measuring absorbance at 254 nm. 
Intestinal 24-OHase Assay 
Intestinal 24-OHase (I-24-OHase) activity was quantified by modifying the method 
previously described by Goff et al (1992). Briefly, approximately 50 mg of mucosal tissue 
was transferred to tubes containing 1 ml of buffer A (0.25 M sucrose, 2 mM dithiothreitol, 
and 40 mM HEPES, pH 7.4,4°C) and prepared as a 5% homogenate. The intestinal 24-
OHase reaction was initiated by adding 150 |xl of homogenate to 10 ng of l,25(OH)2[^H]-
D3, 175 |il of buffer B (22 mM glucose-6-phosphate, 20 mM ATP-disodium salt, 160 mM 
nicotinamide, 0.42 mM NAD+, 0.37 mM NADP+, 7.5 mM succinate, and 0.1 M KHPO4; pH 
7.4,4°C), and 175 |il of buffer C (8 mM MgCl2,100 mM KCl, 200 units/L glucose-6-
phosphate dehydrogenase, and 850 units/L alcohol dehydrogenase). All reagents in buffers 
A, B, and C were bought from Sigma Chemical (St. Louis, MO). The reaction mixture 
incubated for 15 min in a shaking water bath at 37°C. The reaction was terminated by the 
addition of 1.9 ml methanol: methylene chloride (2:1, v/v). The product of the reaction, 
1,24,25(0H)3[^H]-D3, was recovered by lipid extraction (Bligh and Dyer, 1959) and 
chromatographic isolation over straight-phase HPLC (Millipore, Milford, MA). Recoveries 
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were monitored with radioinert l,25,28(OH)3D2 (100 ng). The l,25,28(OH)3D2 metabolite 
eluted close to the tritiated product and eluted as a visible peak on the chromatograph. For 
HPLC, an amino column (Dupont Instruments, Dover, DE) was developed in a solvent 
system consisting of hexane:isopropanol:methanol (88:10:2, v/v/v) at a flow rate of 2 ml/min. 
One min fractions [^Hj-sample were collected and quantified by using a Beckman LS-7800 
scintillation counter (Beckman Instruments, Palo Alto, CA). The intestinal 24-OHase 
activity values were expressed as pg of 1,24,25(OH) 3D 3 per mg cytosolic protein per hr. 
Northern Blot Analysis 
Total RNA was isolated by extraction with acid guanidine isothiocyanate/ 
phenol/chloroform. Poly (A+) RNA was isolated by a batch method using custom prepared 
oligo-dT columns. Samples (20 |ig) of poly (A+) RNA were denatured by heating at 65°C in 
MOPS buffer containing 5 mM sodium acetate, 1 mM EDTA, 2.2 M formaldehyde, and 50% 
formamide (v/v), pH 7.0 for 5 min and electrophoresed in 1.2% agarose gel containing 2.2 M 
formaldehyde. The resolved RNA was transferred to Nytran membrane (Micron Separations, 
Inc., Westboro, MA). The RNA was covalently cross-linked to membrane by ultraviolet 
light using a stratalinker from Stratagene (La Jolla, CA). RNA blots were prehybridized for 
1 to 2 hr at 42°C in a solution containing 50% formamide, 5X SSPE (SSPE = 18 M NaCl, 10 
mM Na2HP04, 1 mM EDTA, pH 7.4), 5 mg/ml of denatured salmon sperm DNA, IX 
Denhardt's solution (2% Ficoll 400, 2% polyvinylpyrrolidone, and 2% bovine serum 
albumin, and 0.5% sodium dodecyl sulfate (SDS). The cDNA probes used in this study were 
as follows: VDR, the 1.7-kb rat cDNA insert from the EcoRI site of pIBI76 (Pike et al., 
1988); 24-hydroxylase, the 3.2-kb rat cDNA insert from the EcoRI site of pUC19 (Ohyama 
et al., 1991); CaBP-28k, the 1.2-kb cDNA insert from the EcoRI site of pIBI76 (Wood et al., 
1988); CaBP-9k, the 0.2-kb mouse cDNA insert from the EcoRI site of Bluescribe (Mifflin et 
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al., 1988); and P-actin, the 2.1-kb chick cDNA insert from the HindlQ. site of pBR322 
(Cleveland et al., 1980). 
The cDNAs were labeled with [a^^PJdCTP by using a random primer procedure 
from Pharmacia Fine Chemicals (Piscataway, NJ) to a specific activity of lO^-lO^ dpm/mg 
DNA. Hybridizations were performed in a solution containing 50% deionized formamide, 
5X SSPE, 100 mg/ml fragmented, low molecular weight fish DNA, 5X Denhardt's reagent, 
and 0.5% SDS at 42°C for 16 hr. Membranes were washed twice in 2X SSPE and twice 
more in O.IX SSPE for 10 min at each wash. The membranes were covered with an 
intensifying screen and exposed to Kodak Xomat X-Ray film (Eastman Kodak CO., 
Rochester, MN) at -70°C. Imaging and quantification of bands were assessed by using an 
AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA) 
Statistics 
Tukey's multiple range test was used to determine significant differences between 
control and treated groups. 
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RESULTS 
Plasma Calcium, PTH, and l,25(OH)2D3 Concentrations 
The effect of normal and excess vitamin Dg on rat plasma Ca, PTH and l,25(OH)2D3 
concentrations is shown in Table 1. Plasma Ca concentration was 11.2 ± 0.13 mg/dl in NC 
rats. The NCT treatment caused hypercalcemia, 14.6 + 0.25 mg/dl (P <0.001). In contrast, 
dietary Ca restriction decreased plasma Ca concentration to 9.1 ± 0.1 mg/dl (P <0.001) in LC 
rats and to 9.7 ± 0.37 mg/dl (P <0.01) in LCT rats. 
By using a radioimmunoassay specific for the N-terminal region of PTH, we 
demonstrated baseline plasma PTH concentrations to be ~45 pg/ml in both NC and NCT 
groups. However, Ca-restricted rats, regardless of vitamin Dg status, showed evidence of 
nutritional hyperparathyroidism with significant (P <0.001) increases in plasma PTH 
concentrations in LC rats (161.6 ± 10.1 pg/ml) and in LCT rats (154.0 ± 19.0 pg/ml). 
Compared with NC rats, significant (P <0.01) decreases in plasma l,25(OH)2D3 
concentrations (115.5 ± 6.9 versus 47.5 ± 8.1 pg/ml) occurred in the NCT group. In LC rats, 
however, plasma l,25(OH)2D3 concentrations increased by 5.3-fold to 615.2 ± 109.7 pg/ml 
(P <0.001), presumably as a result of elevated plasma PTH concentrations. Plasma 
l,25(OH)2D3 concentrations in LCT rats (99.2 ± 11.74 pg/ml) did not change significantly as 
compared to NC rats. 
Evaluation of Kidney and Intestinal VDR Concentrations 
Table 2 shows a comparison of kidney and intestinal VDR concentrations. In NC 
rats, kidney VDR concentration was about half that of intestinal VDR concentration (kidney 
VDR, 200.0 ± 14.3 versus intestinal VDR, 414.0 ± 18.6 fmol/mg protein). The NCT 
treatment resulted in significant up-regulation of VDR concentrations in kidney (541.0 ±21.3 
fmol/mg protein, P <0.001) and intestine (695.0 ± 34.0 fmol/mg protein, P <0.01) tissues. As 
compared to NC rats, kidney VDR in LC rats was down-regulated (115.0 ± 8.3 fmol/mg 
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protein, P <0.01), but intestinal VDR concentration did not change significantly (421 ± 15.1 
fmol/mg protein). As with LC rats, in LCT rats, there was also significant down-regulation 
of kidney VDR 97.0 ± 5.7 fmol/mg, P <0.001, as compared with NC rats. Although, the 
LCT treatment potentiated modest up-regulation of intestinal VDR, the increase was not 
significant, as contrasted to NCT treatment effects in kidney and intestine. 
Evaluation of Kidney and Intestinal Hydroxylase Activities 
Table 3 shows the differential regulation pattern of K-1 a-OHase activities as a result 
of Ca restriction and excess vitamin Dg. A small decrease in K-1 a-OHase activity occurred 
in NCT rats as compared with NC rats. In LC and LCT rats, K-1 a-OHase activity increased 
by 19.0-fold (P <0.001) in LC rats and by 2.3-fold (P <0.05) in LCT rats. 
Table 3 also shows a comparison of the differential regulation patterns of kidney and 
intestinal 24-OHase activities as a result of Ca restriction and excess vitamin D3. Compared 
with hydroxylase activities in the NC, control rats, NCT treatment enhanced K-24-OHase 
activity by 43-fold (P <0.001) and increased I-24-OHase activity by only 2.8-fold. In 
contrast, calcium restriction in LC rats strongly suppressed K-24-OHase activity but 
increased I-24-OHase activity by 11.9-fold (P <0.05). Suppression of K-24-OHase activity 
also occurred in LCT rats, but the increase in I-24-OHase activity was a dramatic 26-fold (P 
<0.001). In comparison, I-24-OHase activity of LCT rats was 9.3 times greater than 1-24-
OHase activity of NCT rats. 
Evaluation of Vitamin D3-Dependent mRNA Expression 
Figure 1 shows the effects of Ca restriction and vitamin D toxicity on steady-state 
measurements of kidney and intestinal mRNA expression of VDR and 24-OHase. The NCT 
treatment increased K-VDR by 3.1-fold (P<0.01) but had no notable effect on intestinal VDR 
mRNA expression, which did not change significantly in any group. In LC rats, kidney VDR 
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mRNA expression was decreased by 50%, but the decrease was not significant. Calcium 
restriction in LCT rats blocked up-regulation of kidney VDR mRNA expression as contrasted 
to the increase in kidney VDR expression of NCT rats. Compared to kidney, I-24-OHase 
mRNA expression was virtually nonexistent in NC rats. Nevertheless, NCT treatment 
increased kidney (5.1-fold) and intestine (10.0-fold) 24-OHase mRNA expression. As 
expected, K-24-OHase mRNA expression in LC rats closely paralleled the observed down-
regulation of 24-OHase activity (Table 3), showing a decrease of 66% (P <0.05). 
Surprisingly, I-24-OHase mRNA expression in LC rats did not increase as contrasted to 
almost a 12-fold increase in I-24-OHase activity (Table 3), indicating potential 
posttranscriptional regulation of I-24-OHase activity in LC rats. In LCT rats, K-24-OHase 
mRNA decreased by 60% (P <0.05); however, I-24-OHase mRNA expression increased 
greatly (44.4-fold, P <0.001). 
Shown in Figure 2 are the effects of Ca restriction and vitamin D toxicity on steady-
state measurements of kidney CaBP_28k and intestinal CaBP.gk mRNA expression. 
Compared to NC rats, K-CaBP-28k increased by 4.7-fold (P <0.01) in NCT rats, but declined 
by 20% in both LC and LCT rats. The 20% decline of K-CaBP-28k in LCT rats did not 
significantly differ from NC rats, but LCT treatment completely blocked up-regulation of 
CaBP-28k mRNA expression, as contrasted to NCT rats. Small increases in I-CaBP.gk 
mRNA expression occurred in all the experimental groups, and in LCT rats the increase in I-
CaBP-Qk mRNA expression was 3.5-fold (P <0.01). 
58 
DISCUSSION 
The regulation of hormone receptor abundance is an important determinant of target 
cell responsiveness (Roth et al., 1979). Several studies demonstrate that pharmacological 
administration of l,25(OH)2D3 and other vitamin D3 metabolites homologously up-regulate 
target tissue VDR (Costa et al., 1985; Mangelsdorf et al., 1987; Goff et al., 1990). What is 
not clear, however, is the magnitude of VDR up-regulation potentiated by l,25(OH)2D3 
under physiological conditions. Moreover, increases in cellular l,25(OH)2D3 attenuate VDR 
turnover by a mechanism of receptor stabilization resulting from ligand binding (Costa and 
Feldman, 1987; Wiese et al., 1992). As a result, in vivo l,25(OH)2D3-mediated up-
regulation of VDR may in some tissues be more a function of extended VDR half-life rather 
than a consequence of increased VDR synthesis. 
In contrast to the results of this study, some investigators have demonstrated small 
steady-state increases in intestinal VDR concentration and VDR mRNA expression after 
prolonged dietary calcium restriction (Favus et al., 1988; Shinki et al., 1992). Results from 
Ca restriction in this study show no significant increases in either intestinal VDR 
concentration or intestinal VDR mRNA expression analyzed from three independent 
Northern blots. An exception was in LCT rats where there was a limited up-regulation of 
intestinal VDR concentration compared with that in NCT rats (Table 2). On the contrary, 
factors induced by dietary calcium restriction caused down-regulation of kidney VDR 
concentration by 50% and suppressed kidney VDR mRNA expression as well. These results 
agree with the results of other groups who have examined kidney VDR regulation during 
dietary Ca restriction (Goff et al., 1990; Sandgren and DeLuca, 1990; Meyer et al., 1992; 
Shinki et al., 1992; Uhland-Smith and DeLuca, 1993). The actual factor or mechanism 
causing down-regulation of kidney VDR has been a matter of controversy, despite the well-
known nature of this effect. 
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Potential candidates for regulating VDR in target tissues during Ca restriction include 
PTH, a low Ca condition, and l,25(OH)2D3-mediated activation of catabolic enzymes. The 
evidence in vitro suggests that low extracellular Ca concentration results in the activation of 
intracellular second messenger systems (Krishnan and Feldman, 1991; Krishnan and 
Feldman, 1992). Furthermore, other studies relate activation of protein kinase C and 
increased production of cAMP with modulation of cellular VDR concentration (van Leeuwen 
et al., 1990a; van Leeuwen et al., 1992; Reinhardt and Horst, 1992). One theory is that 
decreasing extracellular Ca concentration modulates changes in intracellular Ca 
concentration through second messenger signaling (van Leeuwen et al., 1990a). This 
supposition, however, is difficult to prove in vivo. For example, only small decreases in 
extracellular Ca concentrations are required in vivo for exerting very profound changes in 
intracellular second messenger signaling. In addition, cells expend a great deal of energy in 
order to keep intracellular Ca very low (10"^M) relative to extracellular Ca (lO'^M). To 
date, a strong correlation has not been demonstrated between the activation of specific second 
messenger systems with in vivo regulation of VDR during a hypocalcemic condition. 
Reinhardt and Horst (1990) demonstrated in vivo that coinfusion of PTH and l,25(OH)2D3 
into rats blocked homologous VDR up-regulation in both kidney and intestinal tissues and 
inhibited K-24-OHase activity. Rats coinfused with PTH and l,25(OH)2D3, moreover, 
became severely hypercalcemic, which has been proposed as an opposing condition for VDR 
down-regulation (Sandgren and DeLuca, 1990; van Leeuwen et al., 1990b; Uhland-Smith 
and DeLuca, 1993). 
The present study demonstrates that dietary Ca restriction leads to renal insensitivity to 
vitamin D3 and l,25(OH)2D3 action on several known vitamin D-dependent genes. The 
mechanism responsible for the development of this insensitivity is at present unknown. 
However, the similarities among the effect of dietary Ca restriction on VDR and CaBP 
mRNA expressions, and 24-OHase mRNA expression, which is generally considered to be 
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down-regulated by PTH (Shinki et al., 1992), suggest that a role for PTH in the negative 
modulation of l,25(OH)2D3 action in kidney is plausible. However, a permissive effect of 
hypocalcemia acting in conjunction with PTH is worthy of consideration. First, the down-
regulation of kidney VDR was similar in magnitude in both LC and LCT rats. Second, LC 
and LCT rats displayed similar increases in PTH concentration and decreases in plasma Ca 
concentration. Third, the mRNA expression patterns of kidney VDR and kidney CaBP-28k 
closely matched the putative effect of PTH down-regulation of K-24-OHase mRNA 
expression. In contrast to l,25(OH)2D3 actions in kidney, self-induced catabolism of 
1,25(0H)2D3 potentially could be influencing intestinal tissue responsiveness. Self-induced 
catabolism of 1,25(0H)2D3 can limit VDR occupancy (Reinhardt and Horst, 1989). Also, 
ketokonazole, an inhibitor of P-450 mixed function oxidases in vitro (Pols et al., 1987; 
Reinhardt and Horst, 1989b) and in vivo (Reinhardt et al., 1988) has been used to 
demonstrate that blockade of l,25(OH)2D3 catabolism modulates increases in l,25(OH)2D3-
mediated up-regulation of VDR. The fact that dietary calcium restriction leads to a 
considerable increase in I-24-OHase activity (Table 3; Goff et al., 1992), and, concomitantly, 
in vivo intestinal VDR concentrations remain constant (Table 2) provides the first in vivo 
evidence supporting a role of self-induced catabolism as a mechanism for limiting 
homologous VDR up-regulation. Interestingly, intestinal 24-OHase mRNA expression in LC 
rats was not increased significantly. Thus the possibility that increased intestinal 24-OHase 
activity, induced by Ca deficiency is a nongenomic effect of l,25(OH)2D3 action should be 
considered and tested. Alternatively, l,25(OH)2D3 may act to stabilize I-24-OHase mRNA 
transcripts and PTH may act to destabilize K-24-OHase mRNA transcripts. In NCT and LCT 
rats, intestinal 24-OHase mRNA expressions were increased and this reflects what others 
have shown in relation to pharmacological administrations of either vitamin D3 or 
1,25(0H)2D3 to rats (Armbrecht and Boltz, 1991; Shinki et al., 1992; Goff et al., 1992) 
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According to Vieth (1990), susceptibility to vitamin D3 toxicity depends on the 
following: the concentration of plasma vitamin D3 metabolites dissociated from the vitamin 
D binding protein (DBF), the activity of extrarenal la-OHase, and end organ catabolism. In 
the present study we examined K-1 a-OHase activity and estimated end organ catabolism by 
quantifying kidney and intestinal 24-OHase activities. In agreement with Hughes et al., 
(1976), vitamin D3 excess inhibited K-1 a-OHase activity. Also, the degree of inhibition of 
la-OHase activity in NCT rats versus that in NC rats was small because K-1 a-OHase 
activity is inherently low in vitamin Dg-replete rats fed adequate dietary Ca. 
We previously showed that, despite low plasma l,25(OH)2D3 concentrations, vitamin 
D3 toxicity caused intestinal VDR up-regulation (Beckman et al, 1990). Likewise, vitamin 
D3 toxicity also caused kidney VDR up-regulation (Table 2, NCT group). In a vitamin D3 
toxic condition, up-regulation of VDR plus the presence of high concentrations of vitamin 
D3 metabolites induces 'hypersensitivity' of vitamin D3 target tissues. The amount of dietary 
Ca dictates the severity of vitamin D3 toxicity. By implementing calcium restriction, LCT 
rats were spared many of the toxic effects of hypervitaminosis D3. As contrasted to the NCT 
treatment, the LCT treatment caused modest hypocalcemia, increased plasma PTH 
concentrations, and attenuated up-regulation of VDR . 
The increases in plasma PTH concentration of LC and LCT rats as contrasted to 
dissimilar plasma l,25(OH)2D3 concentration (Table 1), indicates either a decreased 
1,25(0H)2D3 synthesis or increased 1,25 (OH) 2D 3 metabolic clearance rate (MCR) in LCT 
rats. The data in Table 3 comparing K-1 a-OHase activity of LC and LCT rats strongly 
indicate an inhibition of 1 a-OHase activity in LCT rats. In addition, we have unpublished 
results that will show a great increase in l,25(OH)2D3 MCR in both NCT and LCT rats. 
Increases in l,25(OH)2D3 MCR are indicative of the high rates of K-24-OHase activity in 
NCT rats and I-24-OHase in LCT rats, respectively. 
62 
In summary, despite profound endogenous increases in plasma l,25(OH)2D3 
concentrations, induced by dietary Ca restriction, several known actions of l,25(OH)2D3 in 
kidney and intestine were in large measure prevented. In kidney tissue, the conditions of 
hypocalcemia and high plasma PTH concentration seemed to cause l,25(OH)2D3 
insensitivity as exemplified by down-regulation of kidney VDR by as much as 50% 
following prolonged Ca restriction, regardless of vitamin D3 status. In intestinal tissue, an 
adaptive mechanism is proposed whereby Ca restriction leads to increased I-24-OHase 
activity via a posttranscriptional signaling pathway, and this in turn accelerates catabolism of 
cellular l,25(OH)2D3 and limits intestinal VDR occupancy. The instability of unoccupied 
intestinal VDR relative to the ligand occupied counterpart (Wiese et al., 1992) may explain 
unchanged intestinal VDR concentrations during Ca restriction. In vitamin D3 toxicity (NCT 
rats), the capacity of I-24-OHase activity was suppressed but intestinal VDR concentration 
increased, despite no increase in intestinal VDR mRNA expression. These results in intestine 
of NCT rats suggest that a prolonged effect of VDR occupancy by either l,25(OH)2D3 or 25-
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Table 1. Changes in plasma Ca, PTH, and l,25(OH)2D3 concentrations in response to dietary Ca restriction and vitamin 












11.2 + 0.1 
14.6 ± 0.3 *** 
9.1 ±0.1 *** 
9.7 ±0.4 **,t 
47.7 ± 2.3 
43.9 ± 2.7 
161.6+10.1*** 
154.0+18.9 ***, t 
115.5 ±6.9 
47.5 ±8.1 
615.2 ± 109.7 *** 
99.2 ± 11.7 
^Values are means ± SEM (n=6). NC, 1.0-1.2% Ca, normal D3; NCT, 1.0-1.2% Ca, excess D3; LC, 
0.02% Ca, normal D3; LCT 0.02% Ca, excess D3. Significant differences were measured by Tukey's multiple 
range test. 
** significant difference at P <0.01 versus NC group 
*** significant difference at P <0.001ver5M5 NC group 
t significant difference at P <0.001 versus NCT group 
Table 2. Changes in kidney and intestinal l,25(OH)2D3-receptor concentrations in response to dietary Ca 
restriction and vitamin D3 excess ^ 
Kidney VDR Intestinal VDR 
Treatment (fmol/mg protein) (fmol/mg protein) 
NC 200.0 ± 14.3 414.0 ± 45.4 
NCT 541.0 ±21.3*** 695.0 ± 69.2** 
LC 115.0 ± 8.3** 421.0 + 29.5 
LCT 97.0 ± 5.7***,t 528.0 ±49.1,¥ 
^Values are means ± SEM (n=6). NC, 1.0-1.2% Ca, normal D3; NCT, 1.0-1.2% Ca, excess D3; 
LC, 
0.02% Ca, normal D3; LCT 0.02% Ca, excess D3. Significant differences were measured by Tukey's 
multiple range test. 
** significant difference at P <0.01 versus NC group 
*** significant difference at P <0.001 ver^M^NC group 
t significant difference at P <0.001 versus NCT group 
¥ significant difference at P <0.1 versus NCT group 
Table 3. Changes in kidney and intestinal 25-OH-D3-hydrolyses in response to dietary Ca restriction and vitamin Dg 
excess ^ 
Kidney la-OHase Kidney 24-OHase Intestinal 24-OHase 
Treatment (pg x hr" 1 jc mg tissue" ^  ) (pg x min" ^ x rag tissue" ^  ) (pgz min" 1 xmg protein" ^  ) 
NC 1.54 + 0.15 6.36 + 0.81 6.73 + 0.80 
NCT 1.05 + 0.10 275.39 ± 14.51*** 18.73 ±7.12 
LC 28.73 ± 5.57 *** ND^ 80.01 + 16.26 * 
LCT 3.59 + 0.41 *t ND 173.76 + 33.28 ***,t 
^Values are means ± SEM (n=6-10). NC, 1.0-1.2% Ca, normal D3; NCT, 1.0-1.2% Ca, excess D3; LC, 
0.02% Ca, normal D3; LCT 0.02% Ca, excess D3. Significant differences were measured by Tukey's multiple 
range test. 
^ND not detected 
* significant difference at P <0.05 versus NC group 
** significant difference at P <0.01 versus NC group 
*** significant difference at P <0.001ver5M5 NC group 
t significant difference at P <0.001 NCT group 
Figure 1. Northern blot analysis of rat kidney and intestinal poly (A+) RNA probed with 
cDNAs for l,25(OH)2D3-receptor, 24-hydroxylase and p-actin genes. Twenty 
|ig of poly (A+) RNA were electrophoresed in a 1.2% agarose gel and transferred 
to nytran membranes. Northern blot analysis was repeated for each probe by 
stripping membranes between hybridizations. The sizes of the bands were 
determined by their position in the gel relative to positions of the 28S and 18S 
rRNAs. The chart below shows the statistical analysis of VDR and 24-OHase 
mRNA expression. Band intensities were quantified with AMBIS Radioanalytic 
Imaging System (see methods). Loading differences were corrected by using p-
actin content as a standard. NC lanes were assigned the arbitrary value of one. 
Significant differences were measured by Tukey's multiple range test. 
(n=3). *= P <0.05; **= P <0.01, significant difference between NC group and 
other groups. ¥ = P <0.05, significant difference between NCT and LCT groups, 









NC NCT LC LCT 
Iff 
NC NCT LC LCT 
Kidney Intestine 
NC NCT LC LCT 
VDR 1 3.08** 0.47 1.45 t 
mRNA expression ±0.52 ±0.09 ±0.39 
24-OHase 1 5.05** 0.33 0.39 *t 
mRNA expression ±0.93 ±0.19 ±0.12 
NC NCT LC LCT 
1 1.74 0.1.24 1.62 
±0.44 ±0.15 ±0.42 
1 10.01** 2.21 44.42 ***t 
±4.07 ±0.69 ±12.31 
Figure 2. Northern blot analysis of rat kidney and intestine poly (A+) RNA probed with 
cDNAs for CaBP-28k. CaBP-9k, and P-actin genes. The chart below shows 
the statistical analysis of calbindin mRNA expression. Band intensities were 
quantified with AMBIS Radioanalytic Imaging System. Loading differences were 
corrected by using P-actin content as a standard. NC lanes were assigned the 
arbitrary value of one. Significant differences were measured by Tukey's multiple 
range test.(n=3). ** = p <0.01, significant difference between NC group and 





3.1Kb - Ê# # 
2.9 Kb - • ^ 
~  I #  -  #  
P-Actin ^ 
2.1Kb "" " If 
NCNCT LC LCT 
Kidney CaBP.28K 
NC NCT LC LCT 
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ABSTRACT 
In the course of studying the role of dietary calcium (Ca) in vitamin D3 toxicity, we 
observed that intestinal 24-hydroxylase (I-24-OHase) mRNA expression was related 
indirectly to plasma calcium concentrations. We studied this effect in more detail in rats 
treated as follows: normal 1.0% Ca diet plus 200 lU vitamin D3 (NC), normal Ca diet plus 
75,000 lU vitamin Dg/wk (NCT), low 0.02% Ca diet plus 200 lU vitamin D3 (LC), and low 
Ca diet plus 75,000 lU vitamin Dg/wk (LCT). I-24-OHase mRNA expression increased by 
3- and 10-fold in LC and NCT groups, respectively, as compared with that in NC rats. The 
LCT group, however, showed a dramatic 45-fold increase in the expression of I-24-OHase 
mRNA. The LCT group became slightly hypocalcemic despite receiving pharmacological 
amounts of vitamin D3. We, therefore, examined the possibility that a calcitonin release in 
response to hypercalcemia observed in NCT rats may have suppressed the vitamin D3 
excess-induced expression of I-24-OHase mRNA. A radioimmunoassay for human 
calcitonin verified a significant (P <0.001) calcitonin increase in NCT rats (36.14 ± 2.46 
pg/ml) versus NC (21.16 + 1.08) and LCT (19.38 ± 2.28) rats. Further examination showed 
that thyroparathyroidectomy (TPTX) of NCT rats resulted in a 2-fold (P <0.001) increase in 
I-24-OHase activity. Furthermore, calcitonin (100 lU/rat) administration to NCT/TPTX rats 
significantly (P <0.001) decreased I-24-OHase activity. Calcitonin administration to LCT 
rats (LCT/CT) also resulted in a significant (P <0.001) decrease in I-24-OHase mRNA 
expression. These data suggest that calcitonin is a potent negative regulator of I-24-OHase 
mRNA expression and I-24-OHase activity, and the release of calcitonin during vitamin D3 




24-Hydroxylation is thought to be the initial step in the inactivation of vitamin D 
metabolites and in particular of 1,25-dihydroxyvitamin Dg [l,25(OH)2D3] (Brommage and 
DeLuca, 1985; Haussier et al., 1988). This contention is supported by the presence of 24-
hydroxylase (24-OHase) activity in most if not all vitamin D target tissues (Armbrecht et al., 
1992). Also, in kidney and intestine, the affinity of 24-OHase for 1,25 (OH) 2D 3 is 5-10 times 
greater than the affinity of 24-OHase for 25-OH-D3 (Tomon et al., 1990; Burgos-Trinidad 
and DeLuca, 1991; Shinki et al., 1992). The production of 24,25(OH)2D3 in the kidney 
represents an alternate pathway from l,25(OH)2D3 production when the content of dietary 
Ca is normal, because the physiological demand for l,25(OH)2D3 action is low during a 
normal Ca state. During hypocalcemic conditions, parathyroid hormone (PTH) blocks renal 
24-OHase activity (Shigematsu et al., 1986) and stimulates renal 1 a-hydroxylation 
(Armbrecht et al., 1984; Henry and Luntao, 1989). Endogenous increases in plasma 
1,25(0H)2D3 concentrations act to increase intestinal 24-OHase (I-24-OHase) activity. In 
rats fed a low calcium (LC) diet, for example, intestinal 24-OHase activity (Shinki et al., 
1992; Goff et al., 1992) increases proportionally with plasma 1,25(0H)2D3 concentration. 
The intestine, therefore, may represent an important quantitative site of 1,25(0H)2D3 
catabolism. 
The one similarity akin to the regulation of kidney and intestinal 24-OHase is 
1,25(0H)2D3-dependence for induction (Matsumoto et al., 1985; Tomon et al., 1990). 
Ohyama et al. (1991) reported the cloning and sequencing of the cDNA for the 24-OHase. 
Initial investigations of the regulation of 24-OHase mRNA expression in l,25(OH)2D3 target 
tissues such as kidney and intestine indicate the regulation of 24-OHase expression is tissue-
specific. Shinki et al. (1992) demonstrated that PTH is a primary down-regulator of renal, 
but not intestinal 24-OHase mRNA expression. Time-course experiments to examine 24-
OHase mRNA expression (Armbrecht and Boltz, 1991) showed that a bolus dose of 
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1,25(0H)2D3 to rats induced an increase in renal 24-OHase mRNA expression beginning at 
3 hr, peaking at 16 hr, and remaining elevated at 48 hr. In contrast, intestinal 24-OHase 
expression was more transient, peaking at 3 hr and being undetectable by 16 hr. 
Furthermore, cell culture experiments done by Armbrecht et al. (1992) confirmed the 
l,25(OH)2D3-mediated induction of renal 24-OHase mRNA expression and demonstrated 
the requirement of new mRNA and protein synthesis for induction of renal 24-OHase mRNA 
by 1,25(0H)2D3. 
The present study examines the effect of the combination of excessive dietary vitamin 
D3 with a dietary Ca deficiency on I-24-OHase. Previously, we found (Beckman et al., 
unpublished data) that I-24-OHase mRNA expression and activity were suppressed in Ca 
sufficient, vitamin D3 toxic rats when compared with Ca deficient, excess vitamin D3-treated 
rats, which do not become hypercalcemic. In the present study, we examined the cause of I-
24-OHase suppression in vitamin D3 toxic rats and demonstrated a role for calcitonin in this 
suppression. 
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MATERIALS AND METHODS 
Chemicals 
Vitamin D3 was purchased from Sigma Chemical (St. Louis, MO). The 
1,25(0H)2D3 and 1,24,25(OH)2D3 standards were generous gifts from Milan Uskokovic 
(Hoffmann-La Roche, Inc., Nutley, NJ). All solvents used in vitamin D metabolite 
extractions were from Burdick and Jackson (Muskegon, MI) or Fisher Scientific (Fairlawn, 
NJ). Phenol was from Armesco (Solon, OH). The [a-32p]dCTP, specific activity 3000 
Ci/mmol, was obtained from Amersham Corp. (Arlington Heights, IL). Random primer 
32p-labeling kits were from Pharmacia Fine Chemicals (Piscataway, NJ). The cDNA probes 
were as follows: VDR, the 1.7-kb rat cDNA insert from the EcoRI site of pIBI76 (Pike et al., 
1988); 24-hydroxylase, the 3.2 kb rat cDNA insert from the EcoRI site of pUC19 (Ohyama et 
al., 1991); CaBP-9k, the 0.2-kb mouse cDNA insert from the EcoRI site of Bluescribe 
(Mifflin et al., 1988); and (î-actin, the 2.1-kb chick cDNA insert from the HindUl site of 
pBR322 (Cleveland et al., 1980). Calcitonin radioimmunoassay kit was from Nichols 
Institute Diagnostics (San Juan Capistrano, CA). Salmon calcitonin (Calcimar ®) was from a 
local pharmacy. 
Diets and Animal Experiments 
Protocols for the use of animals were approved by the USDA National Animal 
Disease Center's Institutional Animal Care and Use Committee. Weanling (21 day old) male 
rats (Harlan Sprague-Dawley) ate for 2 wk a purified vitamin D3-sufficient Ca (NC) diet 
(Teklad, Madison, WI) containing 1.0% Ca and 0.3% phosphorus. Then, half of the rats 
were switched to a low Ca (LC) diet (0.02% Ca and 0.3% phosphorus). One wk later, half of 
the rats from each group were given excess vitamin D3 at a rate of 25,000 lU 3 times per wk. 
The rats were given a total of 8 administrations of excess vitamin D3, and these groups were 
designated NCT and LCT. At the end of the administration period, the rats were rendered 
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unconscious with C02:02 (50%:50%, v/v), euthanized and decapitated. Blood was collected 
into tubes containing heparin, and intestinal mucosa was scraped from the first 15 cm of the 
duodenum. 
An additional 20 rats from the NCT group were used in a separate experiment. 
Following the third dose of excess vitamin D3,10 of these rats underwent 
thyroparathyroidectomy (TPTX) surgery following anesthetization with C02:02 (50%:50%, 
v/v) and light isoforane inhalation during the surgical procedure. After removal of the 
thyroid and parathyroid glands from the rats, surgical incisions were sutured with autoclips. 
The other 10 rats remained as sham-operated controls. After surgery, we resumed excess 
vitamin D3 administrations for a total of 8 doses as specified in the original experimental 
design. Additionally, we injected calcitonin (100 lU/rat) intraperitoneally (IP) into 3 rats 
from each group 4 hr before euthanizing the rats. Blood was collected, and intestinal 
mucosal cells were scraped from rat duodena and used for measurement of 24-OHase activity 
as described by Goff et al. (1992). 
Additional LCT-treated rats (4 rats per group ) were used in a final experiment. Four 
hr before euthanizing the rats, we injected one group of rats IP with calcitonin (100 lU/rat). 
At the end of the experiment, blood was collected into tubes containing heparin and intestinal 
mucosa was scraped. In this experiment, intestinal mucosa was quick-frozen in liquid N2 for 
subsequent mRNA analysis. 
Northern Blot Analysis 
Total RNA was isolated by extraction with acid guanidine isothiocyanate/phenol/ 
chloroform. Poly (A+) RNA was isolated by a batch method using custom prepared oligo-dT 
columns. Samples (20 |Xg) of poly (A+) RNA were denatured by heating at 65°C in MOPS 
buffer containing 5 mM sodium acetate, 1 mM EDTA, 2.2 M formaldehyde, and (50% v/v) 
formamide; pH 7.0 for 5 min and subjected to electrophoresis in 1.2% agarose gel containing 
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2.2 M formaldehyde. The resolved RNA was transferred to Nytran membrane (Micron 
Separations, Inc., Westboro, MA) and covalently cross-linked to the membranes by 
ultraviolet light by using a stratalinker (Stratagene, La Jolla, CA). RNA blots were 
prehybridized for 1 to 2 hr at 42°C in a solution containing 50% deionized formamide, 5X 
Denhardt's reagent, 0.5% sodium dodecyl sulfate (SDS), 5X SSPE (SSPE = 18 M NaCl, 10 
mM Na2P04, 1 mM EDTA, pH 7.4), and 100 mg/ml fragmented low molecular weight fish 
DNA. The VDR, 24-OHase, CaBP-9k, and P-actin cDNAs were labeled by using an [a^^P]-
dCTP random primer kit from Pharmacia Fine Chemicals (Piscataway, NJ). RNA blots were 
hybridized for 16 hr at 42°C in the same solution used for the prehybridization. Membranes 
were washed twice in 2X SSPE at room temperature and twice in 0. IX SSPE at room 
temperature. The membranes were exposed to Kodak Xomat X-Ray film (Eastman Kodak 
CO., Rochester, MN) at -70°C with an intensifying screen. Imaging and quantification of 
bands were assessed by using an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San 
Diego, CA) 
Statistics 
The Student-Newmann-Keuls multiple range test were used to determine significant 
differences between control and treated groups. 
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RESULTS 
Vitamin D-Dependent mRNA Expression 
Figure 1 shows the effects of dietary Ca and excess vitamin Dg on vitamin D-
dependent mRNA expression for three Ca regulation proteins. After correcting for loading 
differences by normalizing to p-actin, we saw no significant changes in either I-VDR or I-
CaBP-9k mRNA expression in any of the treatment groups. In contrast to I-VDR and I-
CaBP-9k mRNA expression, I-24-OHase mRNA expression was very low in NC rats but 
increased 10-fold in NCT rats, 3-fold in LC rats, and 45-fold in LCT rats. Table 1 shows the 
effects of low dietary Ca and excess vitamin Dg on plasma Ca and calcitonin concentrations. 
The NCT rats became hypercalcemic as the result of excessive dietary vitamin Dg. In 
contrast, there were significant decreases in plasma Ca concentrations of LC rats (P <0.001) 
and LCT rats (P <0.01). Plasma calcitonin concentrations of NC rats were 21.16 ± 1.08 
pg/ml. Hypercalcemia of NCT rats was associated with an increase in plasma calcitonin 
concentrations to 36.14 ± 2.46 pg/ml (P <0.001). However, in LC rats, plasma calcitonin 
concentrations decreased slightly to 15.94 ± 0.94 pg/ml, and in LCT rats plasma calcitonin 
concentrations did not decrease (19.38 ± 2.28 pg/ml) but were significantly (P <0.001) lower 
than plasma calcitonin concentrations of NCT rats. 
Effect ofTPTX Surgery on 1-24-OHase Activity 
We examined the possibility that the increase in plasma calcitonin concentrations of 
hypercalcemic NCT rats was responsible for the lower I-24-OHase expression as compared 
to LCT rats. Some of the rats underwent TPTX following 3 doses of excess vitamin Dg to 
remove the influence of calcitonin. As shown in Figure 2, the effect ofTPTX in NCT rats 
resulted in nearly a 2-fold increase (P <0.001) in intestinal 24-OHase activity. We also gave 
injections of calcitonin to NCT and NCT/TPTX rats 4 hr before euthanizing the rats. The 
calcitonin administered to NCT rats had little effect on I-24-OHase, but a significant (P 
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<0.001) down-regulation of I-24-OHase did occur in NCT/TPTX rats. Therefore, exogenous 
calcitonin administration did not potentiate the suppression of I-24-OHase in NCT rats. On 
the other hand, exogenous calcitonin given to NCT/TPTX rats caused a very strong 
suppression of I-24-OHase. 
Ejfect of Acute Administration of Calcitonin 
To investigate if calcitonin acts directly on the I-24-OHase system and if the putative 
direct action modulates I-24-OHase gene expression, we designed an additional experiment. 
Shown in Figure 3 are Northern analysis of 24-OHase mRNA expression, the statistical 
analysis of 24-OHase mRNA expression (n=4), and plasma calcium concentrations in 
response to LCT treatment and calcitonin administration. The result of this experiment is 
very clear in that calcitonin administration to LCT rats dramatically decreased I-24-OHase 
mRNA expression by 5.0-fold (P <0.001) within just 4 hr. Moreover, calcitonin 
administration to LCT rats mediated a decrease in plasma Ca concentration (LCT average 




To date, there has been little evidence for the involvement of calcitonin in vitamin D 
metabolism, with the exception of a minor role in increasing 1 a-OHase activity (Horiuchi et 
al., 1979; Kawashima et al., 1981). On the contrary, several studies, all of which have led to 
negative results, have been performed both in vitro and in vivo examining potential direct 
effects of acute calcitonin administration on intestinal calcium transport (Olson et al., 1972; 
Cramer, 1973; Gray et al., 1973; Swaminathan et al., 1974; Kisloff and Moore, 1977; 
Walling et al., 1977). In contrast to these studies, our results suggest that increased calcitonin 
release during vitamin Dg toxicity causes suppression of I-24-OHase mRNA expression and 
activity. Removal of thyroid and parathyroid glands reversed the suppression and allowed 
for a 2-fold increase in I-24-OHase activity. Furthermore, an acute IP administration of 
calcitonin only 4 hr before the termination of the experiment dramatically decreased 1-24-
OHase mRNA expression in LCT rats, indicating a very rapid response by calcitonin. 
The study of the 24-OHase and its tissue-specific regulation is important because of 
the potential of 24-hydroxylation for modulating l,25(OH)2D3 action. Of particular interest 
is the intestine. Its function in Ca absorption is fundamental for supporting bone formation 
by providing adequate Ca uptake from the diet. A current theory is that C-24 hydroxylation 
of 1,25(0H)2D3 is the initial step in the catabolism of l,25(OH)2D3 and in limiting the 
action of l,25(OH)2D3 in target tissues (Napoli and Horst, 1983; Brommage and DeLuca, 
1985; Haussier et al., 1988). Increases in the expression and activity of 24-OHase may be an 
essential mechanism for counteracting excessive l,25(OH)2D3 action in target tissues 
(Reinhardt and Horst, 1989). In calcium deficiency, l,25(OH)2D3 is increased greatly, but 
this increase in hormone does not stimulate up-regulation of intestinal VDR (Goff et al., 
1990), however, I-24-OHase activity is significantly increased (Goff et al., 1992) by an 
apparent posttranslational mechanism (figure 1). Its probable that increased I-24-OHase 
activity during Ca deficiency is a mechanism for modulating VDR concentration in response 
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to excessive plasma l,25(OH)2D3 concentrations. In the present study, partial blockade of I-
24-OHase in NCT rats by calcitonin may have prolonged the action of l,25(OH)2D3 or 25-
OH-D3, and thus explain, in part, the development of uncontrolled intestinal Ca absorption 
during vitamin D3 toxicity. 
Furthermore, Goff et al. (1992) demonstrated that dietary phosphorus restriction 
prevents l,25(OH)2D3-mediated up-regulation of I-24-OHase activity, even though plasma 
1,25(0H)2D3 concentrations increased by 4-fold. As with vitamin D3 toxicity, 
hypercalcemia also occurs in phosphorus deficiency, and while purely speculation, an 
increase in calcitonin release during phosphorus deficiency may account for the lack of 
observed 1,25(OH) 2D3-mediated I-24-OHase induction. Interestingly, a study by Meyer et 
al. (1992) showed that the phosphorus deficient condition in chickens led to up-regulation of 
intestinal VDR. A similar up-regulation of intestinal VDR does not occur with dietary Ca 
restriction (Goff et al., 1992; Meyer et al., 1992; Figure 1). 
A study by Jaeger et al. (1986) indirectly supports our contention that calcitonin 
enhances l,25(OH)2D3 action in the intestine. In their study, constant calcitonin 
administration to TPTX rats fed normal vitamin D3 and adequate Ca led to an increase in 
plasma Ca concentrations from a hypocalcemic range to a low normal range. The Jaeger 
study ran for 13 days. On day 6, plasma l,25(OH)2D3 concentration increased in calcitonin-
treated rats by 2-fold compared with that in untreated control rats (80 pg/ml versus 38 pg/ml). 
On day 9, plasma Ca concentration had increased by 50% and was maintained at this higher 
concentration until day 12. However, on day 13, plasma l,25(OH)2D3 had returned to 
control l,25(OH)2D3 concentrations. The study of Jaeger suggested that calcitonin increased 
intestinal Ca absorption, despite the lack of a commensurate increase in plasma l,25(OH)2D3 
at the latter stage of the experiment. The work of Jaeger might be explained in the following 
way. Initially, calcitonin may have raised plasma l,25(OH)2D3 concentrations and at the 
same time suppressed I-24-OHase activity. Suppression of I-24-OHase activity would have 
86 
extended l,25(OH)2D3 action in the intestine, and might explain why plasma Ca 
concentrations increased through day 9. As plasma Ca concentrations increased to the 
normal range, l,25(OH)2D3 production would have decreased, but suppression of 1-24-
OHase may have continued, which would explain why plasma Ca concentrations were 
maintained within the normal range out to day 12 of the Jaeger study. 
The distribution of receptors for calcitonin (CTR) includes bone osteoclasts 
(Nicholson et al., 1986) where calcitonin acts to inhibit osteoclastic bone resorption (Holtrop 
et al., 1974) and kidney (Marx et al., 1973) where calcitonin stimulates reabsorption of 
urinary Ca^+ as well as several other ions (Di Stefano et al., 1990). However, 
characterization of calcitonin receptors in intestinal mucosa of rat awaits more detailed 
investigation. 
The putative suppression of I-24-OHase by calcitonin may have clinical implications 
in disorders that manifest hypercalcemia such as sarcoidosis. In other words, calcitonin-
mediated suppression of I-24-OHase could potentially exacerbate the condition of 
sarcoidosis, a hypercalcemic syndrome of l,25(OH)2D3 overproduction (Bell et al., 1979). 
Therefore, it may be efficacious in the management of certain hypercalcemic conditions to 
lower dietary Ca in combination with treatment therapies to aid in reversing the suppression 
of I-24-OHase activity by calcitonin. Alternatively, a method might be employed to slow the 
release of calcitonin such as thyroidectomy or anti-calcitonin drug therapy. 
The question one might ask is, what is the fundamental purpose for such regulation of 
I-24-OHase? The answer to this question may relate to the physiological role of 24-OHase, 
which is generally thought of as a catabolic step in the metabolism of 1,25 (OH) 2D 3 
(Bronraiage and DeLuca, 1985). In the rat, induction of I-24-OHase by l,25(OH)2D3 occurs 
more readily than does K-24-OHase induction, with a maximal response of 3hr in intestine 
compared with 16hr in kidney (Armbrecht and Boltz, 1991). This suggests that the rat makes 
adjustments to a hypocalcemic state by first enhancing renal l,25(OH)2D3 production, and 
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secondly by modulating l,25(OH)2D3 action at extrarenal sites, particlarly the intestine. 
Calcitonin may then be the off signal for I-24-OHase and potentially other extrarenal 24-
OHase sites. This set of interactions may be an important endocrine communication network 
between renal and extrarenal sites involved in regulating vitamin D physiology. 
In summary, we demonstrate a potentially novel role of calcitonin in suppressing I-
24-OHase expression. Such an action may block an important inactivation pathway of 
vitamin Dg metabolites and may worsen the condition of vitamin D3 toxicity. 
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Figure 1. Northern analysis of the expression of I-24-OHase, I-VDR, and I-CaBP mRNA and p-
actin mRNA in rats in response to dietary Ca restriction and vitamin D3 excess. 
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Table 1. Changes in plasma calcium and calcitonin concentrations in response to dietary Ca 
restriction and vitamin Dg excess ^ 
Plasma Calcium Plasma Calcitonin 
Treatment (mg/dl) (pg/ml) 
NC 10.44 + 0.25 21.16+ 1.08 
NCT 11.79 ±0.14*** 36.14 + 2.46*** 
LC 9.06 ± 0.13*** 15.94 + 0.94 
LCT 9.47 ± 0.15**,t 19.38 ± 2.28t 
^Values are means ± SEM (n=6). NC, 1.0% Ca, normal D3; NCT, 1.0% Ca, excess D3; LC, 0.02% 
Ca, normal D3; LCT 0.02% Ca, excess D3. Significant differences were measured by the Newmann-Keuls 
multiple range test. 
* significant difference at P <0.05 versus NC group 
** significant difference at P <0.01 versus NC group 
*** significant difference at P <0.001 versus NC group 
t significant difference at P <0.001 versus NCT group 
Figure 2. Intestinal 24-OHase activities in NCT compared to NCT rats that underwent 
thyroparathyroidectomy (NCT/TPTX), NCT rats given 100 lU calcitonin (NCT/CT), and 
NCT/TPTX rats given calcitonin (NCT/TPTX/CT). Presented are means ± SEM. 
Significant difference from NCT group, *** = P <0.001. Significant difference from 
NCT/TPTX group, f = P <0.001. 
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Figure 3. Northern analysis of the expression of I-24-OHase mRNA and p-actin mRNA, means ± 
SEM of relative densities from mRNA expression analysis, and plasma Ca concentrations 
in response to LCT treatment and LCT/CT treatment. Significant difference from LCT 
group, *** = P <0.001. 
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In addition to shedding new light on mechanisms influencing vitamin Dg toxicity, this 
research project provides new information concerning the regulation of l,25(OH)2D action 
and VDR in target tissues of rats. An understanding of the mechanisms regulating 
1,25(0H)2D action in various target tissues is important to the interpretation of the 
relationship of plasma l,25(OH)2D concentration, which is often measured in clinical 
settings for disorders of mineral metabolism and metabolic bone diseases. 
The action of l,25(OH)2D is dependent upon three major components; plasma 
1,25(0H)2D concentration, tissue VDR content, and tissue-specific metabolism of 
1,25(0H)2D. The factors regulating renal 1 a-OHase activity and plasma l,25(OH)2D 
concentration are well studied, but during vitamin D3 toxicity there may be additional 
extrarenal sites of l,25(OH)2D3 synthesis, induced by the presence of excess circulating 25-
OH-D3 substrate, that work to maintain stable plasma l,25(OH)2D3 concentrations. Much 
of this putative extrarenal 1 a-OHase activity may occur in bone tissue, which has been 
shown to possess the potential for 1 a-OHase activity . Increases in target tissue VDR during 
vitamin D3 toxicity would further enhance 1,25(OH) 2D3 action. Also, the finding that 
intestinal 24-OHase is suppressed, probably by calcitonin, provides a rationale for why 
vitamin D toxicity is an exacerbating syndrome. The essential feature of vitamin D3 toxicity 
is that of hypercalcemia, evidenced by the fact that the hypocalcemic LCT group in this study 
did not show outward signs of vitamin D3 toxicity. Furthermore, intestinal 24-OHase in 
LCT rats increases in great disproportion to that of hypercalcemic NCT rats while VDR 
concentrations in LCT rats seems suppressed compared with NCT rats. 
The in vivo regulation of VDR is extremely complex involving the combined action 
of: calcitropic hormones, physiological stresses, dietary Ca and P status, and several 
noncalcitropic hormones including estrogen, glucocorticoid, retinoic acid, and thyroid 
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hormone. In addition, many cellular factors have been shown to affect VDR regulation such 
as cAMP/protein kinase A, IPg/protein kinase C, and fos/jun, however, the exact nature of 
the regulation these cellular factors exert on VDR in vivo awaits further investigation. The 
data from this study indicate differential responsiveness to increased plasma l,25(OH)2D3, 
induced by Ca restriction, in kidney versus intestine. In kidney, PTH, which also increases 
during Ca restriction, may have decreased VDR as much as 50%. In intestine, Ca restriction 
led to increased intestinal 24-OHase activity, and the resulting accelerated l,25(OH)2D3 
catabolism may have so limited VDR occupancy as to suppress an increase in VDR 
concentration. Suppression of intestinal 24-OHase activity in vitamin D toxicity and possibly 
other hypercalcemic states such as dietary phosphorus restriction and sarcoidosis may be 
permissive in contributing to the severity of hypercalcemia. This study elucidates calcitonin 
as the hypercalcemic factor suppressing intestinal 24-OHase activity and it was shown that 
calcitonin injections to LCT rats could suppress rapidly intestinal 24-OHase mRNA 
expression. The suppression of intestinal 24-OHase during vitamin D3 toxicity may block an 
important inactivation pathway for the inactivation of vitamin D3 metabolites in the intestine. 
An area perhaps important for future study will be a more comprehensive 
investigation the regulation of 24-OHase in both classical and non classical l,25(OH)2D3 
target tissues. In addition, the purification of 1 «-hydroxylase and the cDNA cloning of la-
OHase would be of tremendous interest to the field, as this has been a missing piece of the 
vitamin D puzzle for many years. 
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